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Intermediate purity factor VIII concentrates have greatly improved care for haemophilia
sufferers but have been implicated in contributing to subclinical immunomodulation
observed in vivo. During the course of factorVIII replacement therapy haemophilia
patients are repeatedly exposed to an enormous number of allogeneic protein
contaminants and this substantial protein load may be responsible for establishing
immunological abnormalities. Indeed, it has been proposed that intermediate purity
factor VIII concentrates could accelerate the rate of disease progression in those
haemophiliacs infected with the human immunodeficiency virus. Highly purified factor
VIII preparations are now available commercially, but are extremely expensive
compared to conventional intermediate purity concentrates and their use must therefore
be justified in terms of patient benefit.
This study sets out to investigate whether intermediate purity factor VIII concentrates
could contribute to immune abnormalities observed in haemophilia patients in viva
This problem has been approached by investigating the effects of various factor VIII
preparations on immune stimulation in vitro.
A range of factor VIII preparations were included in a number of proliferation assays.
Peripheral blood lymphocytes were stimulated with mitogens, recall antigen or
allogeneic stimulator cells. The effect of factor VIII concentrates on lymphocyte
proliferation was monitored by recording ^H-thymidine incorporation, cytokine
production or cell surface activation marker expression post stimulation.
The results demonstrate that intermediate purity factor VIII concentrates can modulate
lymphocyte proliferation in vitro. SNBTS intermediate purity factor VIII preparations
inhibited lymphocyte proliferation following PHA stimulation but enhanced lymphocyte
activation following stimulation with irradiated allogeneic lymphoblastoid cells. In
contrast, highly purified factor VIII preparations had no effect on immune stimulation
following a number of activation signals. Although the factor(s) responsible for the
observed immune modulation in vitro have not been identified, several potential
candidates have been excluded. The immunomodulatory effect of some intermediate
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purity factor VIII preparations in vitro may partially account for immunological
imbalance observed in haemophilia patients.
In lymphocytes infected with HIV, intermediate purity factor VIII concentrate has been
shown to enhance lymphocyte proliferation and virus replication following stimulation
with irradiated allogeneic stimulator cells. Factor VIII infusions could potentially
accelerate disease progression in HIV infected haemophilia patients by a similar
mechanism to that observed in vitro.
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INTRODUCTION
1 Factor VIII replacement therapy
Factor VIII deficiency or haemophilia A is a hereditary bleeding disorder confined
almost entirely to males. A reduction in factor VIII activity in the blood coagulation
causes uncontrollable haemorrhage which must be stopped by the intravenous
administration of factor VIII.
Historically whole blood or fresh frozen plasma have been used as a source of
replacement factor VIII. However, in 1964 it was discovered that factor VIII could be
partially purified by precipitation in the cold and subsequently cryoprecipitate became the
chosen form of therapy (Pool et al, 1964). In the early 1970s lyophilized factor VIII
concentrate was introduced and has remained in use to date (Shanbrom and Thelin,
1969). Recently high purity factor VIII concentrates have been developed using
ion-exchange chromatography ormonoclonal antibodies to purify factor VIII from
human plasma (Burnouf et al, 1991, Brettler et al, 1989, Weinstein, 1989). In
addition, preliminary clinical trials using synthetic factorVIII prepared by recombinant
DNA technology are under way (White et al, 1989, Schwartz et al, 1990). These
highly purified but costly preparations are however not yetwidely available to the
majority of haemophilia sufferers in the United Kingdom.
Factor VIII concentrates have substantially improved the ease and effectiveness of
substitution therapy but they have also introduced transfusion-associated complications
(Aronson, 1988, Johnson et al, 1985).
Factor VIII concentrate is manufactured from very large pools of human plasma (eg.
5-30,000 donations) and thus carries the risk of transmitting a number of blood-borne
viruses. Lyophilized factor VIII concentrate has been associated with the transmission
of hepatitis B virus, hepatitis C virus, parvo virus and human immunodeficiency virus
(Norkrans et al, 1981, Fletcher et al, 1983, Mortimer et al, 1983, Williams et al,
1990, Simmonds et al, 1990, Kitchen etal, 1984, Jones et al, 1985).
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Following the inadvertent exposure to HIV and infection of a large number of
haemophiliacs, in 1984 virus inactivation steps were introduced into the manufacturing
process of factor VIII concentrates. Approaches to virus inactivation vary from wet or
dry state heating (Spire et al, 1985, Levyetal, 1985, Schimpf et al, 1989) to
ultraviolet irradiation in conjunction with beta propiolactone (Prince et al, 1983) and
treatment with organic solvents and detergents (Horowitz et al, 1985, Feinstone et al,
1983). Heat treatment results in factor VIII concentrates of comparable therapeutic
value to unheated concentrates although there is some loss (approximately 10-20%) of
factor VIII activity during the viral inactivation procedures (McGrath et al, 1985).
Most factor VIII used in the treatment of haemophilia A patients is of intermediate
purity. In some cases as little as one percent of the lyophilized product is actually factor
VIII, the vast majority of material being fibrinogen, immunoglobulin, fibronectin and
other plasma proteins. Although some protein contaminants are not antigenic in their
native state, manufacturing procedures may lead to the formation of aggregated or
denatured proteins capable of stimulating the immune system. In particular, new
antigenic epitopes may be created during heat treatment or other virus inactivation steps.
Haemophiliacs may also be exposed to alloantigens such as erythrocyte blood group
antigens during the course of their treatment.
The method of heating factor VIII concentrate can alter the polypeptide structure of
factor VIII (Kemball-Cook et al, 1990). In particular, pasteurization (60°C for 10
hours) leads to an increase in factor VIII breakdown as does heating lyophilized powder
in organic solvent suspension (60°C for 20 hours) rather than ordinary dry heating
(60°C for 36 hours). Although some protocols for virus inactivation result in increased
factor VIII protein degradation, it is not clear whether product immunogenicity is altered
in parallel. To date there is no evidence to support this possibility.
Allain et al (1985) compared the biochemical and immunological characteristics of a
heated factor VIII concentrate with an identical non-heated preparation. Rabbits were
inoculated intradermally with either the heated or non-heated factor VIII product.
Antisera raised were tested by double immunodiffusion in agarose gel against both
concentrates, fibronectin and fibrinogen. Precipitin line profiles were identical for
heated and non-heated preparations as immunogen suggesting the heat-treated product
contained no new antigenic determinants.
It has been postulated that the huge antigenic load patients are exposed to may modulate
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the haemophiliac immune system in some manner. It is possible that factor VIII
concentrates of variable composition and purity produced by different manufacturing
processes may affect the immune system to differing extents.
2 The immune system
The human immune system comprises a complex inter-related network of organs, cells
and specialised proteins including antibodies, cytokines and complement. Following
antigenic challenge cells of the immune system interact to respond appropriately in a
controlled, co-ordinated fashion.
Antigen presenting cells at various sites throughout the body internalise, process and
present antigen on their cellular membranes. Antigen fragments are presented in the
context of host major histocompatibility antigens. Antigens are presented to helper T
lymphocytes which are central to the development of immune responses. They can
enhance the activity of B cells to produce antibody and that of cytotoxic T cells, via the
production of lymphokines. Activated helper T cells may also modulate the activity of
NK cells, macrophages, granulocytes and antibody-dependent cytotoxic cells.
Antigen presenting cells not only present antigen fragments, but produce a number of
cytokines essential to the regulation and response of the immune system (Hildemann,
1984). It is clear that interference with any component part of the immune system could
potentially disrupt the entire immune response. Intermediate purity factor VIII
concentrates may therefore affect general immune status via modulation of lymphocyte
and monocyte function.
3 Blood components and immunosuppression
A growing body of data supports the proposal that blood transfusions have
immunological effects on patients and experimental animals beyond those of
alloimmunisation to blood cell antigens (Woodruff and van Rood, 1983).
3.1 Immunological abnormalities in haemophilia patients
(i) Immune abnormalities in vivo
It has been clear for a number of years that some haemophilia patients undergoing
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treatment with factor VIII preparations have subclinical abnormalities of the immune
system. Patients tend to have reduced T helper:T suppressor/cytotoxic ratios due to
depressed numbers of CD 4+ cells and in some cases increased numbers of CD 8+ cells
(Saidi, 1983, Menitove, 1983, Lederman, 1983, Lechner, 1983, Kessler, 1983,
Jones, 1983).
In 1982 a number of haemophilia patients were found to be suffering from the acquired
immunodeficiency syndrome, AIDS (Centers for Disease Control, 1982). However,
immunological abnormalities were present in many haemophilia patients in the absence
of full blown AIDS. At this time it was not clear whether immune modulation in
haemophiliacs was related to viral infection by a putative AIDS virus, some feature of
nonA nonB hepatitis, or indeed a consequence of intensive factor VIII concentrate
usage. Although it became clear that HIV, the virus responsible for AIDS, could be
transmitted via the transfusion of blood products and many haemophiliacs were indeed
infected with HIV (Centers for Disease Control, 1986), a role for factor VIII
replacement therapy in establishing immune imbalance in haemophilia patients was not
completely excluded.
More recent studies have confirmed that immunological abnormalities occur in patients
suffering from haemophilia, irrespective of HIV infection. Reduced CD 4+ cell
numbers, increased CD 8+ cell numbers and reduced CD4:CD8 ratios all occur in HIV
seronegative haemophilia patients receiving factor VIII concentrates (Carr et al, 1984,
Berntorp et al, 1989, Rickardetal, 1983, Moffat etal, 1985, Gilletal, 1985,
AIDS-Haemophilia French Study Group, 1985). Depressed CD4:CD8 ratios have
also been reported in anti-HIV negative haemophiliacs treated with ciyoprecipitate
(Ceuppens et al, 1984, Hollanetal, 1985).
The cell mediated immune response may be assessed by the intradermal injection of
standard doses of recall antigens. Haemophilia A patients challenged with a panel of
recall antigens show impaired reactivity, irrespective of HIV antibody status (Mclvor et
al, 1987). Madhok et al (1986) evaluated the cell mediated immune response in a
group of haemophiliacs from Glasgow by means of the dinitrochlorobenzene (DNCB)
skin test. Cell mediated immunity was depressed in both HIV positive and HIV
negative patients. In addition, an inverse relationship between exposure to clotting
factor concentrate and DNCB skin response was observed.
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Immune abnormalities unrelated to HIV infection are readily demonstrable in
haemophilia patients. However, abnormalities may be a result of haemophilia per se or
a consequence of intensive factor VIII replacement therapy with blood products.
The significance of subclinical immune imbalance in haemophiliacs is unclear. Altered
CD4:CD8 ratios may indicate abnormal regulation of the immune response or some
other defect in T cell mediated immunity. However, the composition of lymphocyte
subsets in blood is affected by a number of conditions. Altered CD4:CD8 ratios have
been reported in an enormous number of disease states (Westermann and Pabst, 1990).
Reduced responsiveness to recall antigens following intradermal challenge may be
related to a defect in T cell or antigen presenting capabilities.
The clinical consequences of subtle immunological abnormalities in haemophilia patients
seem to be relatively limited. Madhok et al (1987) report a rare case of extranodal
non-Hodgkin's lymphoma in a haemophilia patient seronegative for HIV. The authors
propose that reduced cell mediated immunity may have contributed to the pathogenesis
of the tumour in this patient.
One might predict that patients with reduced cell mediated immunity would be more
susceptible to viral infections, tumours and intracellular bacterial infections (Hildemann,
1984).
Chronic persistent hepatitis is more likely to progress to more serious forms of liver
disease in haemophilia patients than in non haemophiliacs with this condition (Triger and
Preston, 1990). Progression to chronic active hepatitis and even cirrhosis has been
recorded within as little as five years. It is difficult to determine whether severe liver
disease in haemophilia patients is related to increased susceptibility to hepatitis virus
infection ormerely a result of virus exposure. Although a single episode of infection
can result in chronic persistent hepatitis, repeated exposure and/or infection may
compound the severity and progression of liver disease.
Rosendaal et al (1989) calculated mortality figures for a group of 717 Dutch
haemophiliacs between 1973 and 1986. When compared to the general male
population, cancermortality was significantly higher (2.5 times) than expected. More
than half the excess cancer mortality was caused by lung tumours. Ischaemic heart
disease was significantly reduced in this group of patients. Increased cancer mortality
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is also suggested in a report by Aronson et al (1988).
There have been no reports of an increased incidence of lymphoma in haemophilia
patients. However, in a study of AIDS-associated non-Hodgkin lymphoma in the
USA, lymphoma was found to be most common in patients with haemophilia or
clotting disorders (Beral et al, 1991).
Deaths in haemophilia patients in the United Kingdom from 1976 to 1980 were analysed
by Rizza and Spooner (1983). Although the study reports a near normal median life
expectancy in patients with severe haemophilia, it also highlights an unusually high
incidence of deaths from pneumonia in patients suffering from haemophilia A.
However, these data should be interpreted with caution. In this study, the incidences
of deaths from various causes were calculated on the basis of death certificate analysis.
It is possible that pneumonia may not have been the only, or principal cause of death,
but may have been recorded on the death certificate nevertheless. Pneumonia may arise
as a complication of underlying disease such as following a stroke due to intracranial
haemorrhage.
Haemophiliacs appear to be unusually susceptible to Mycobacterium tuberculosis
infection (Beddall et al, 1983). In an outbreak of the disease in hospital, the frequency
of pulmonary tuberculosis in boys with bleeding disorders was found to be significantly
greater than in patients with other paediatric conditions. The incidence of pulmonary
tuberculosis in haemophiliac boys was similar to that in immunocompromised children
receiving cytotoxic chemotherapy for leukaemia and solid tumours. Furthermore, there
was a significant correlation between the amount of factor VIII replacement therapy
received and the development of evidence of tuberculosis infection.
(ii) Immune abnormalities in vitro
A number of studies have evaluated immune function in vitro using peripheral blood
mononuclear cells from haemophiliacs.
Both peripheral blood lymphocytes and CD 4+-enriched T cells show reduced
responsiveness to the non-specific T cell mitogen PHA in both HIV seropositive and
HIV seronegative patients. In contrast, responses of the haemophiliac to CMV and
HSV-2 viral recall antigens do not significantly differ from those of healthy control
subjects (Mahir et al, 1988).
It is unlikely that low proliferative responses to PHA in vitro are due to excessive
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suppressor T cell activity as CD 8+ depleted T cell cultures from haemophilia patients do
not respond normally to PHA stimulation (Mahir et al, 1988).
Haemophiliacs have a reduced capacity to produce interleukin 2 following PHA mitogen
stimulation in vitro (Madhoketal, 1990). Impaired IL2 production is independent of
HIV-1 antibody status, mean annual dose of factor VIII clotting concentrate
administered and liver disease severity. Similarly, peripheral blood mononuclear cells
from multitransfused haemophiliacs have a diminished capacity to produce IFN-y in
response to induction with PHA, irrespective of HIV antibody status (Ruffault et al,
1988).
T cell proliferation in response to autologous Escherichia coli-pulsed monocytes is
significantly decreased in patients with haemophilia as compared to healthy controls.
This defect is not associated with exposure to HIV and not related to annual factor VIII
usage (Mannhalter et al, 1986). It is not clear whether aberrant antigen processing and
presentation or impaired T cell reactivity is responsible for the observed poor response.
Monocytes from haemophilia patients certainly seem to be abnormal. Sternbach et al
(1987) report alterations in monocyte function including impaired chemotaxis, increased
Candida pseudotropicalis killing and reduced adhesion to plastic.
The infusion of factor VIII preparations can modulate levels of circulating immune
complexes and affect the mononuclear phagocytic system in vivo. In a small series,
Kimberly et al (1984) reported that although individual patient responses to factor VIII
infusion varied, there was a correlation between changes in mononuclear phagocyte
function and circulating immune complexes.
Pasi and Hill (1990) investigated monocyte phagocytic function in six haemophiliac
boys before and one hour after factor VIII infusion. Five of the boys were anti-HIV
seronegative. Monocyte phagocytic function was assessed by the ingestion of
anti-Rh(D) sensitized 0 Rh(D) positive erythrocytes and was significantly impaired
following factor VIII infusion.
Repeated infusions of factor VIII concentrate caused monocyte phagocytic function to
become more impaired. Recovery to normal baseline levels of monocyte phagocytic
function occurred as treatment was reduced. The effect of repeated factor VIII infusion
onmonocyte function was investigated in only three haemophiliac boys. Although two
of the boys were undergoing surgery, the third had not. Similar patterns of inhibition
were observed for each boy. Surgery per se was therefore not solely responsible for
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reduced phagocytic function.
Immunological abnormalities in haemophilia patients are not confined to T lymphocytes
and monocytes. Polymorphonuclear cells from haemophilia patients have significantly
impaired chemotactic, phagocytic and killing capabilities when compared to normal
controls. PMN functions are diminished regardless of HIV infection (Antonaci et al,
1988).
HIV seronegative haemophiliacs have impaired proliferative responses to
Staphlvococcus aureus. Immunoglobulin secretion by plaque-forming cells in vitro
following stimulation with PWM is also reduced (Gorski et al, 1986). However,
spontaneous immunoglobulin production in vitro is elevated in haemophilia patients
when compared to normal, healthy controls (Jin et al, 1989). Similarly, serum IgG
levels are abnormally high in haemophiliacs. Some haemophiliacs also appear to have
elevated titres of autoantibodies directed against both nuclear and cytoplasmic
specificities (Matheson et al, 1987).
The observed B cell abnormalities in haemophilia patients are consistent with chronic B
cell activation in \iva B cell abnormalities appear to be unrelated to the amount or type
of factor VIII replacement therapy received. In fact, B cell abnormalities are present,
although less profound, in the small number of haemophilia patients who have received
very little or no factor VIII substitution therapy (Jin et al, 1989). Similarly, NK cell
activity is low in haemophilia patients regardless of whether or not they have received
blood products (Porzsolt et al, 1984). The abnormality is not correlated with HIV
exposure. It is probable that the NK cell defect is functional as the number of cells
bearing NK cell markers in haemophiliacs is normal (Jin et al, 1989). NK cells from
haemophilia patients show impaired responsiveness to IFN-P and IFN-y (Matheson et
al, 1986).
It is possible that immune dysfunction in haemophiliacs may be genetically determined
rather than a consequence of blood product exposure. This has not to date been
convincingly demonstrated.
Larger, more complete studies of "virgin" or previously untransfused haemophilia
patients are required before a genetic predisposition to immunological imbalance can be
confirmed or refuted. This type of study is, of course, very difficult to perform.
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Most patients with severe haemophilia, who might be expected to have the most
profound abnormalities, are diagnosed at six to twelve months of age when the immune
system in normal babies is immature.
3.2 Immunological abnormalities in patients receiving blood transfusions
Gascon et al (1984) reported immunological abnormalities in patients receiving multiple
blood transfusions. Patients included in the study group suffered from sickle cell
disease, beta thalassemia and sideroblastic and idiopathic refractory anemias. NK cell
function was severely depressed in transfusion recipients.
Reduced NK cell activity was not related to the underlying disease process and was
apparently a result of transfusion. NK cell activity was normal in patients suffering
from sickle cell disease who had never been transfused or who were no longer receiving
transfusions. Indeed, the degree of NK cell activity was inversely related to the
amount of blood transfused.
Although CD4.CD8 T cell ratios were normal in this group of patients, virtually all
patients receiving regular packed erythrocyte transfusions had markedly elevated levels
of HLA.DR positive T cells. Furthermore, HLA.DR expression was abnormal in
patients with a history of transfusion who were no longer receiving red blood cells.
This suggests that the administration of packed erythrocyte transfusions can lead to
chronic T cell activation.
It must be noted that the HIV antibody status of patients included in this study is
unknown and some immunological abnormalities may be related to underlying HIV
infection.
The screening of all blood donations for antibody to HIV (then termed human
T-lymphotropic virus type III) in the United States was not introduced until 1985.
Early in 1985 the frequency of units of blood collected which were consistantly positive
for HIV specific antibodies was 0.25% (Leads from the MMWR, 1985). Patients with
thalassemia major and sickle cell disease who receive transfusions of packed
erythrocytes have abnormally high levels of serum IgG and P2-micr°gl°bulin
(AIDS-Hemophilia French Study Group, 1985). However, this may reflect chronic
hepatitis rather than immune modulation due to transfusion of blood products alone.
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3.3 Graft survival in renal transplant patients
The administration of blood transfusions prior to renal transplant is beneficial to kidney
graft survival. Opelz et al (1978) demonstrate a striking correlation between the number
of pretransplant blood transfusions and improved transplant survival.
The mechanism responsible for improved allograft survival is unknown, although it is
conjectured that the establishment of immunological tolerance or non-specific
immunosuppression may play a role.
Transplantation studies in animals support a role for blood transfusions in establishing
immune tolerance.
In a prospective study of kidney allograft survival in rhesus monkeys, animals
receiving five consecutive pretransplant blood transfusions showed a four-fold increase
in mean survival time compared to non-transfused controls (van Es et al, 1977).
Patients on regular haemodialysis prior to renal transplantation have suppressed cell
mediated immunity, as assessed by a quantitative DNCB skin test. Weak DNCB
reactors have a significantly higher graft survival rate when compared to strong DNCB
reactors (Watson et al, 1979). The number of blood transfusions received is correlated
with reduced response to DNCB (Schot and Schuurman, 1986).
Fischer et al (1980) investigated the effect of blood transfusions on cell mediated
immunity in previously nontransfused prospective kidney graft recipients. Patients
received leukocyte-poor blood transfusions and their cellular immunity was assessed by
recording lymphocyte responses to mitogen and antigen stimulation in vitro. A marked
suppression of cellular immunity which was more pronounced and prolonged following
a second transfusion was demonstrated. The authors propose transfusion-induced
suppression of cell mediated immunity may be mediated by a non-specific suppressor
cell. Similarly, Klatzmann et al (1983) describe nonspecific suppression to allogeneic
cells generated in vivo by blood transfusion.
It is unclear whether depressed cell mediated immunity following the administration of
blood transfusions is long lasting or indeed sufficient to cause clinically recognisable
immune deficiency. One might predict that such immune suppression could result in an
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increased incidence of tumours or other malignant disorders in organ transplant
recipients. Investigating the frequency of such diseases in transplant recipients is
complicated by their dependence on immunosuppressive drug regimens which ensure
continued graft survival.
3.4 Cancer recurrence rates
A number of studies have shown an association between perioperative blood
transfusions and cancer recurrence rates in patients undergoing cancer surgery. Patients
suffering from various tumours, including cancer of the colon, rectum, lung, breast
and cervix in addition to soft tissue sarcomas are reported to have significantly higher
rates of recurrence following transfusion (Burrows and Tartter, 1982, Blumberg et al,
1985, Foster etal, 1985, Tartter etal, 1984, Hymanetal, 1985, Tartter et al,
1985, Blumberg et al, 1985, Rosenberg et al, 1985). However, most of these
studies were carried out retrospectively by analysing medical records and are therefore
subject to biases. In particular, it is probable that patients with unfavourable
prognostic factors were more likely to receive more blood transfusions at the time of
surgery.
Blumberg et al (1986) present data from patients with colonic, rectal, cervical and
prostate tumours. A proportional hazards risk analysis showed that transfusion of any
whole blood or more than three units of erythrocytes was significantly associated with
earlier recurrence and death due to cancer. It was concluded that some factor present in
greater amounts in whole blood, such as plasma, may contribute to the increased risk
of recurrence in patients who have undergone transfusion. Presumably reduced cell
mediated immune surveillance or NK cell activity resulting from blood transfusion
allows the spread of malignant cells to proceed unchecked.
3.5 Tumour survival in animals
In a ratmodel, Francis and Shenton (1981) investigated the effects of blood transfusion
on the growth of transplanted chemically induced sarcoma. Transplants grew more
rapidly in rats that had received transfusions of allogeneic blood than in rats that had
received syngeneic blood, or had not been transfused.
The growth of transplanted tumours in mice is promoted by transfusions involving
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different H-2 antigens. The effect is especially evident when transfusions of whole
blood, plasma, or lymphocytes are administered. Transfusions of erythrocytes alone
do not result in increased tumour growth (Horimi et al, 1983).
3.6 Foetal tolerance in pregnancy
The clinical consequences of blood product transfusion are consistent with the
hypothesis that transfusion of blood in some way results in generalized immune
suppression.
Allogeneic components of themajor histocompatibility complex may trigger an
immunoregulatory mechanism which results in immune suppression. Indeed, the
immunosuppressive events following parenteral or anal MHC alloantigenic challenge
have been likened to maternal immunosuppression during pregnancy (Hoff and
Peterson, 1989). Whereas immunosuppression of pregnancy is generally localized to
the uterus, parenteral or anal exposure to MHC alloantigens results in systemic immune
suppression.
Although a mother is exposed to foreign foetal MHC antigens in early pregnancy, the
allogeneic foetus is not rejected. This is in stark contrast to the rejection of MHC
incompatible transplantation grafts (Medawar, 1944).
The degree of foetal alloantigenic challenge depends on how similar maternal and
paternal HLA haplotypes are. Paradoxically, the greater the MHC alloantigenic
challenge, the more favourable a pregnancy is likely to be in terms of reduced risk of
spontaneous abortion, foetal growth retardation and maternal morbidity (Mogil and
Wegmann, 1989).
In some instances, couples with unexplained infertility or increased rates of
spontaneous abortion share more HLA antigens than is usual (Komlos et al, 1977,
Gerencer et al, 1979). In these circumstances infertility can be overcome by
transfusing leukocyte-enriched plasma throughout pregnancy (Taylor and Page Faulk,
1981).
In some pregnant women, the suppressive immune response to paternally inherited
foetal alloantigens is not localized to the maternofoetal interface. McMichael and
Sasazuki (1977) describe how lymphocytes from a multiparous woman fail to respond
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to allogeneic lymphocytes from her husband in a mixed lymphocyte reaction. The
effect is due to antigen specific T suppressor cells.
Antilymphocyte immunoglobulins found in sera from muciparous women (Payne and
Rolfs, 1958, van Rood et al, 1958) are specific for both foetal and paternal
lymphocytes. Maternal y-globulin concentrate prepared from clotted blood in placental
tissue recovered post partum, is immunosuppressive to kidney transplant patients.
Renal graft survival rate is improved following transfusion ofmaternally-derived
Y-globulin concentrate (Riggio et al, 1978).
It is not known if immune suppression subsequent to blood product transfusion and
foetal tolerance during pregnancy are related. However, exposure to MHC
alloantigens may well play a crucial role in both phenomena.
4 Virus infection in haemophilia patients
There can be no doubt that immunological abnormalities are present in haemophilia
sufferers. It is however, difficult to state with certainty that immune abnormalities
arise because of blood product exposure.
Very few groups have been able to study the effects of factor VIII concentrate in the
absence of confounding effects from HIV infection, chronic liver disease or infection
with hepatitis C or hepatitis B viruses. Each of these factors may well interact to
complicate the situation further. For instance, it is possible that intermediate purity
factor VIII infusions in some way alter HIV disease progression. Immunosuppressive
concentrates might make HIV infected haemophilia patients more susceptible to
opportunistic infection. Alternatively, immunostimulatory products could enhance
virus replication thus contributing to more rapid HIV disease progression. Similarly, it
has been suggested that HIV-induced immunosuppression may allow nonA nonB
hepatitis or hepatitis B infections to proceed unchecked (Madhok et al, 1990).
It seems unlikely that all immune abnormalities are secondary to liver disease. Both
haemophilia A and haemophilia B patients suffer from similar liver problems, yet
haemophilia A patients tend to have more profound immunological abnormalities when
compared to haemophilia B patients. Haemophilia A patients use more units of factor
VIII activity than haemophilia B patients use factor IX. In addition, factor VIII
preparations contain more protein contaminants than factor IX concentrates, which tend
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to be of greater purity.
Studies assessing the immunological status of previously untransfused patients, who
have received only heat treated or high purity factor VIII are required to clarify this
situation.
Evans et al (1991) have recently presented a study of this type on fifteen haemophilic
boys who were treated exclusively with heat treated BPL 8Y concentrate. This
preparation has not been associated with the transmission of hepatitis B virus, HIV or
hepatitis C virus (Pasi and Hill, 1989, Skidmore et al, 1990). Preliminary results
suggest that treatment with 8Y concentrate does not lead to altered CD 4+ or CD 8+ T
cell numbers. However, the boys have been observed for under three years and
should be monitored prospectively for some time. BPL 8Y concentrate has
approximately ten times more factor VIII activity per mg of protein compared to SNBTS
Z8 concentrate.
If immune abnormalities in vivo are a consequence of immunosuppression by
intermediate purity factor VIII concentrates, the introduction of highly purified
preparations may reduce such immune modulation. However, the absence of
concentrate-induced immunosuppression could theoretically lead to increased factor VIII
inhibitor formation . Although early inhibitor development in association with the use
of highly purified factor VIII has been reported (Bell et al, 1990), the true incidence of
inhibitory antibodies remains controversial.
5 Patients receiving Scottish National Blood Transfusion Service intermediate
purity factor VIII concentrate
5.1 Immunological abnormalities
In the Spring of 1983 a study assessing the immunological status of haemophilia
patients attending the Edinburgh Haemophilia Centre was undertaken (Carr et al, 1984).
The original purpose of the study was to investigate modifications in the immune system
related to haemophilia itself and the effect of therapeutic factorVIII concentrates on
immunological parameters.
Patients included in the study had been treated exclusively with factor VIII and factor IX
products manufactured from blood donations collected locally by the Scottish National
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Blood Transfusion Service. At that time no case of AIDS had been reported in Scotland
and it was therefore assumed that the haemophilia patients under investigation were not
latently infected with the (then) putative AIDS virus. Immunological abnormalities
demonstrated in this study group were therefore attributed to the infusion of factor VIII
concentrates per se rather than infection by the human immunodeficiency virus.
Retrospective testing of stored serum samples has confirmed that the patients were
anti-HIV negative at the time of the study.
Immunological alterations were observed in both haemophiliaA and haemophilia B
patients. Haemophilia A patients demonstrated reductions in absolute total lymphocyte
and total T cell counts. The T lymphocytopenia resulted from a reduction in T helper
cells. T suppressor/cytotoxic cell counts were normal. Approximately half the
haemophilia A patients had reduced CD4:CD8 ratios. A small group of haemophilia B
patients included in the study also had depressed CD4:CD8 ratios. This was due to a
slight decrease in the mean T helper cell number and a slight increase in
suppressor/cytotoxic cell numbers. There was no correlation between abnormalities of
circulating lymphocyte subsets and severity of haemophilia, amount of substitution
therapy received, abnormalities of liver function or immunoglobulin concentrations.
Cell mediated immunity in this group of patients was assessed in terms of reactivity to
intradermally injected recall antigens. Patients receiving SNBTS factor VIII concentrate
had depressed intradermal delayed type hypersensitivity responses. The degree of
responsiveness to recall antigens was inversely related to mean annual factor VIII
consumption (Ludlam, 1988). This implies that SNBTS factor VIII concentrate has a
suppressive effect on cell mediated immunity.
5.2 The Edinburgh haemophilia cohort
On follow-up, a number of haemophiliacs in the Edinburgh study group were found to
have developed antibodies to HIV-1 (Ludlam et al, 1985). A few patients had received
commercial factor VIII, whilst others had previously been treated with cryoprecipitate.
However, transfusion records indicated that the majority of HIV infected patients had
received factor VIII from a single batch of contaminated SNBTS factor VIII concentrate.
Blood for this batch of factorVIII was collected in 1983 when HIV infection in the
Scottish blood donor population was very low. It is therefore possible that haemophilia
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patients transfused with this batch of factor VIII were exposed to a single strain of HIV
(Simmonds et al, 1988).
In total 32 haemophiliacs were inadvertantly exposed to HIV from this batch between
March and May 1984. Eighteen haemophilia patients subsequently developed
antibodies to HIV-1 between April and November 1984 while fourteen patients
remained seronegative after receiving the contaminated batch of factor VIII. These
thirty-two patients form the Edinburgh haemophilia cohort. Individuals exposed to the
contaminated batch of factor VIII concentrate who did not develop antibodies to HIV do
not show evidence of latent HIV infection in that they do not have any clinical stigmata
of HIV, have stable CD 4+ counts and are HIV PCR negative (Peutherer et al, 1990).
The probability of HIV seroconversion was related to the number of vials of the
implicated batch transfused. A batch of factor IX concentrate prepared from the same
pool of contaminated plasma was administered to eight patients with haemophilia B and
two haemophilia A patients with anti-factor VIII inhibitors. None of these individuals
seroconverted.
When compared to other longterm investigations of HIV infection the study of the
Edinburgh haemophilia cohort is unique for three important reasons. In the first
instance, members of the cohort have been immunologically assessed prior to HIV
exposure. Second, the period of exposure to HIV has been precisely defined and
finally, the patients are presumed to be infected by the same source; probably a single
virus strain.
5.3 Immunological abnormalities relating to HIV infection
Members of the Edinburgh haemophilia cohort have now been assessed clinically and
immunologically for a period of eight years.
Patients infected with HIV have shown a progressive decline in mean CD 4+
lymphocyte numbers with concomitant increases in plasma P2-microglobulin and
neopterin. Since 1987 individuals seropositive for HIV antibody have also had raised
levels of plasma IgA and increased mean CD 8+ T lymphocyte numbers. In contrast,
HIV seronegative members of the cohort have remained immunologically stable,
although somewhat abnormal (Cuthbert et al, 1990).
A proportion of HIV seronegative haemophilia A patients have unusually high levels of
30
plasma P2-microglobulin, IgG, IgM and IgA in addition to low CD 4+ T lymphocyte
counts. Immunological abnormalities do not correlate with extent of factor VIII usage
or disturbance of liver function tests (Cuthbert et al, 1992).
Three years after initial examination, cell mediated immunity was reassessed in the
Edinburgh haemophilia cohort. Cell mediated immunity in patients positive for HIV
antibody was found to have declined further. Most patients were completely anergic or
responsive to one recall antigen only. The level of cell mediated immunity in HIV
seronegative patients has remained constant.
5.4 HIV disease progression
Long term follow-up of the Edinburgh haemophilia cohort has revealed that the rate of
progression to clinical AIDS in this group of HIV positive haemophiliacs is relatively
rapid. Four years after exposure to HIV 50% of infected patients had progressed to
CDC group IV disease (Steel et al, 1988). Ragni and Kingsley (1990) estimate an
AIDS incidence of 12%, 28% and 49% after four, six and 7.5 years of infection in a
cohort of haemophiliacs in western Pennsylvania. Another report estimated the
incidence of AIDS to be 18% six years following seroconversion (Eyster et al, 1987).
The calculated ten year cumulative incidence of AIDS was 52% in 63 patients attending
the Royal Free Hospital Haemophilia Centre whose date of seroconversion was known
(Leeetal, 1990).
In a large study of haemophilia patients in the United Kingdom, Darby et al (1989)
report the rate of progression to AIDS in HIV positive individuals depends strongly on
age. The cumulative incidence of AIDS five years after seroconversion was found to be
4% among patients aged <25 years at first test positive for HIV, 6% among those aged
25-44 years and 19% among those aged 45 years or over. In contrast, a progression
rate of approximately 10% over 6-8 years in Swedish haemophiliacs has been reported
by Berntorp et al, (1989), who suggest the use of high purity factor VIII concentrates
in the treatment of HIV positive haemophilia patients may be beneficial and postpone
progression to AIDS.
There are a number of explanations for the rapid immunological and clinical decline
observed in members of the Edinburgh haemophila cohort. For instance, the cohort
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may be infected by a particularly virulent strain of HIV. It is possible that co-infection
by other viral pathogens may also contribute to the observed rate of decline in the
cohort. For example, cytomegalovirus infection is reported to be associated with more
rapid disease progression in HIV positive haemophiliacs (Webster et al, 1989),
although this point remains controversial.
It is unlikely that Scottish haemophiliacs suffer from significantlymore viral infections
than other haemophilia patients, although this has not been formally investigated.
There is good evidence to support a genetic influence on the rate of progression of HIV
infection to AIDS in the Edinburgh haemophilia cohort.
In the cohort as a whole a weak association between the HLA haplotype Al B8 DR3 and
an increased risk of seroconversion on exposure to HIV has been noted (Steel et al,
1988). However, in those haemophiliacs who are HIV positive this haplotype is
strongly associated with a rapid decline in circulating CD 4+ cells and development of
HIV related symptoms within four years of infection.
The Al B8 DR3 haplotype had been associated with the C4A null allele of complement
in addition to autoimmune conditions such as systemic lupus erythematosus (Carrol et
al, 1987, Dawkinsetal, 1983). It has been proposed that Al B8 DR3 positive
individuals are immunologically hyperactive. As HIV replicates preferentially in
activated lymphocytes (Margolick and Fauci, 1987), viral replication and dissemination
may occur more readily in individuals bearing this haplotype.
The association between Al B8 DR3 and rapid progression to HIV-related symptoms
and AIDS has been confirmed in two non-haemophiliac cohorts (Kaslow et al, 1990,
Mallal et al, 1990).
Genetic background may not be the only factor affecting disease progression in the
Edinburgh haemophilia cohort. Immunomodulatory effects of locally produced
SNBTS factor VIII concentrates may influence the incidence of AIDS in HIV positive
haemophiliacs.
5.5 SNBTS intermediate purity factor VIII concentrate
The SNBTS factor VIII concentrate is manufactured at the Protein Fractionation Centre
Edinburgh from frozen human plasma (Mcintosh et al, 1987). The product is prepared
from plasma volumes requiring up to 4 000 donations of plasma using a method based
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on extraction from controlled cryoglobulin precipitate (Newman et al, 1971, James and
Wickerhauser, 1972). Plasma derived from blood collected locally from volunteer
donors is screened for the presence of the hepatitis B surface antigen and since 1985 for
antibodies to the human immunodeficiency virus before being used. The concentrate is
heated at 80°C for 72 hours in the dried state in order to inactivate blood-borne viruses.
The reconstituted product is termed of intermediate purity and contains a mixture of
factor VIII, fibrinogen, immunoglobulin, albumin and other plasma proteins in
addition to salts and sugars used in formulating the concentrate. Trace contaminants
such as metal ions and endotoxins are introduced during the manufacturing process.
6 Factor VIII concentrate and immune modulation
6.1 Effect of factor VIII preparations on lymphocyte activation
Immunomodulatory effects of factor VIII preparations are readily demonstrable in vitro.
However, it is difficult to compare reports of immunosuppression due to variation in
concentrates investigated and specific assay conditions.
(i) Lymphocyte proliferation
North American and Scottish intermediate purity factor VIII concentrates inhibit
lymphocyte proliferative responses to non-specific mitogens in a dose-dependent
manner in vitro. Reductions in PHA- and ConA-induced transformation occur when
factor VIII is incubated with normal or haemophiliac peripheral blood lymphocytes
(Froebel et al, 1983). Commercial factor VIII concentrates also inhibit lymphocyte
transformation following stimulation with the monoclonal antibody OKT3 (Wang et al,
1985). Purified factor VIII, fibrinogen or fibronectin, at concentrations comparable to
those found in commercial factor VIII concentrates cause no inhibition of lymphocyte
proliferation. Similarly, the additives glycine and citrate do not consistently inhibit
lymphocyte proliferation. Wang et al propose that inhibition of lymphocyte
proliferation is mediated by a low molecular weight component of factor VIII
preparations. The inhibitory effect is abrogated following concentrate dialysis.
It seems unlikely that in vitro lymphocyte proliferation is inhibited by factor VIII
directly. Neither column-purified factor VIII activity nor antigen causes significant
inhibition of PHA-induced lymphocyte stimulation (Daul et al, 1985). Similarly, the
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highly purified factor VIII preparation Monoclate is totally devoid of
immunosuppressive activity in both human mixed lymphocyte reactions and
PHA-induced lymphocyte proliferation assays (Schreiber et al, 1987).
Citrate added to factor VIII preparations as a stabiliser and anticoagulant may well affect
proliferative responses to stimulation in vitro. McDonald et al (1985) suggest reduced
proliferation in response to lectins and the recall antigen purified protein derivative of
tuberculin (PPD) are related to citrate concentrations in blood products. Intermediate
purity Scottish factor VIII concentrate, stable plasma protein solution and salt-poor
albumin, blood products which contain citrate, are all strongly inhibitory to lymphocyte
mitogenesis. These products do not inhibit proliferation following dialysis. The
authors report that buffer used in the manufacture of Scottish factor VIII and sodium
citrate, when present at comparable concentrations, both inhibit lymphocyte
proliferation in a dose-dependent fashion. In contrast, human normal
immunoglobulin, a citrate-free preparation, has no effect on lymphocyte
transformation. Citrate may inhibit lymphocyte proliferation by reducing the availability
of calcium and possibly other cations necessary for lymphocyte activation in vitro.
Conflicting data identifying two putative inhibitory substances in commercial lyophilized
factor VIII preparations are presented by Lederman et al (1986). Gel filtration of factor
VIII concentrate revealed two peaks of inhibitory activity of molecular weight >2X10^
Da and approximately 6X10^ Da. The authors suggest factor VIII itself or a substance
bound to or co-migrating with factor VIII inhibits lymphocyte proliferation. In
contrast, following gel filtration, fractions of intermediate molecular weight from some
factor VIII preparations actually enhanced lymphocyte proliferative responses to PHA.
Such fractions did not stimulate lymphocyte cultures in the absence of mitogen.
The inhibitory effect of factor VIII transformation appears not to be secondary to an
effect on monocyte function (Hay et al, 1990). Factor VIII inhibits lymphocyte
proliferation in response to phorbol-myristate-acetate (PMA) in the presence or absence
of monocytes. The activation of T cells by PMA is not reliant on the presence of
monocytes.
(ii) IL2 production
Factor VIII preparations inhibit the production of interleukin 2 by human lymphocytes
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and Jurkat tumour cells following mitogen stimulation (Lederman et al, 1986). As IL2
production by Jurkat cells does not require IL1, it is probable the inhibition of IL2
production induced by factor VIII is not mediated via effects on IL1.
Inhibition of lymphocyte proliferation by factor VIII concentrate is not corrected by the
addition of exogenous IL2 (Hay et al, 1990). It is therefore unlikely that factor VIII
preparations reduce responsiveness to mitogens and antigens by suppression of IL2
secretion alone.
Thorpe et al (1989) investigated the effects of six factor VIII products used in the United
Kingdom on IL2 secretion by human T cells. A range of activities was apparent,
varying from total inhibition to no significant effect on IL2 production. No obvious
relationship between protein composition and the level of inhibition was found. It is
interesting to note, however, that inhibition was observed in the presence of both factor
VIII and factor IX preparations, which contain citrate. In contrast, no inhibition
occurred in the presence of albumin or immunoglobulin products, which do not contain
citrate.
(iii) Activation marker expression
Intermediate purity factor VIII concentrate inhibits the expression of cell surface
activation markers on both CD 4+ and CD 8+ T lymphocytes following stimulation with
PHA (Hay et al, 1990). The expression of CD 25, the interleukin 2 receptor, is most
profoundly affected but the percentage of peripheral blood lymphocytes expressing the
transferrin receptor (CD 71) and HLA. DR positive cells are also reduced. It must be
noted that factor VIII was included in proliferation assays at a non-physiological
concentration of 4iu/ml. This level of factor VIII activity is not achieved during
substitution therapy.
6.2 Effect of factor VIII preparations onmonocyte function
In vitro abnormalities in immunological function following exposure to factor VIII are
not confined to T lymphocytes.
Factor VIII concentrate preparations have the capacity to modulate monocyte function in
vitro. Fc receptors expressed on the monocyte plasma membrane are down regulated
following a short (1 hour) exposure of normal monocytes to factor VIII concentrates
(Eibl et al, 1987). Monocyte effector functions are also impaired in terms of capacity
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to kill bacteria and oxygen radical release following stimulation with opsonized zymosan
and aggregated IgG.
Fc dependent monocyte phagocytic function is inhibited by factor VIII concentrates, as
determined by the ingestion of anti-Rh (D) sensitized O Rh (D) positive erythrocytes
(Pasi and Hill, 1990). Monoclonal antibody-purified factor VIII is significantly less
inhibitory compared to conventional intermediate purity concentrates. The degree of
impaired monocyte function is unrelated to mode of virus inactivation, but decreases as
product purity increases.
The contaminant present in factor VIII concentrate responsible for impaired monocyte
function may be immune complexes or IgG aggregates (Eibl et al, 1987).
6.3 Effect of factor VIII preparations onNK cell function
NK cell lytic activity of normal peripheral blood lymphocytes against K562 tumour
targets is significantly reduced following preincubation with factor VIII (Albin et al,
1986, Lederman et al, 1986).
Published in vitro immunomodulatory effects of factor VIII are summarised in Table 1.
The clinical importance of factor VIII or impurities in factor VIII formulations in
modulation of immune function both in vivo and in vitro remains to be clarified. It has
implications for the manufacture of all blood products as well as being of importance in
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The aims of this thesis were as follows;
1. To investigate the nature of effects of various commercial factor VIII
preparations on in vitro lymphocyte responses to mitogens.
2. To assess quantitative and time course aspects of these effects.
3. To relate effects to the levels of purity of different factor VIII preparations.
4. To derive some information on the possible identity of the contaminant(s) in
factor VIII products responsible for the observed immunological effects.
5. To determine whether the observed effects on lymphocyte proliferation might be
related to HIV replication in vitro.
6. To deduce whether the in vitro influence of factor VIII preparations on
lymphocyte responses might explain some of the clinical features of disease
progresion in HIV infected haemophiliacs treated with intermediate purity factor
VIII.
The experimental approaches to these aims are summarised below;
1. Standardised lymphocyte proliferation (^H-thymidine incorporation) assays;
titration ofmitogens, antigen and stimulator cells. Time course 1-12 days.
2. Compared effects of factor VIII concentrates of differing purity levels in
proliferation assays.
3. Related activity in vitro to published concentrate composition.
4. Using preparation shown to be active in the above assays (SNBTS Z8),
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physical manipulation and fractionation was attempted as follows;
(i). Filtered and freeze-thawed.
(ii). Defibrinated.
(iv). Passed through molecular weight cut off filters.
(v). Attempted depletion of HLA. DR, factor VIII and fibronectin with
specific antibodies.
5. In \itro activity of the Z8 and its derived fractions in lymphocyte proliferation
assays was assessed simultaneously after each of these stages.
6. Measured effects of factor VIII on cell proliferation and simultaneous virus




1.1 Peripheral blood mononuclear cells (PBMC)
Peripheral blood mononuclear cells were isolated from venous blood drawn into lithium
heparin or from buffy coats (Blood Tranfusion Centre, Edinburgh, UK) collected from
healthy human blood donations (citrated). Buffy coat samples were defibrinated using
sterile orange sticks following the addition of 200p,l bovine thrombin ( Pentex
Products, Kankakee, Illinois) reconstituted in 1M calcium chloride. Fresh orange
sticks were used to stir the blood gently and remove clots formed until complete
defibrination had occurred.
Peripheral blood mononuclear cells were isolated from fresh and defibrinated blood
samples by centrifugation over Ficoll/Hypaque (SG 1.077, Parmacia, Uppsala,
Sweden) at 900g for 15 min (50% brake). The interface formed containing
mononuclear cells was removed and washed in phosphate buffered saline (PBS).
Residual erythrocytes were removed as required by the addition of 0.17M ammonium
chloride for 10 min on ice followed by RPMI 1640 (Gibco, Grand Island, NY)
supplemented with 0.03% fresh glutamine and 5% heat inactivated foetal calf serum
(FCS). Mononuclear cells were then washed two times in PBS.
All reagents were sterile and sterile handling procedures were followed throughout.
1.2 AET-SRBC
Sheep red blood cells (SRBC) pelleted from defibrinated sheep blood and stored at 4°C
in sterile Alsever's solution (Scottish Antibody Production Unit, Carluke, UK) were
centrifuged over Ficoll/Hypaque at 900g for 15 min (50% brake). The interface
containing residual sheep mononuclear cells was removed and discarded. One ml
SRBC, measured from the packed cell pellet, was washed three times in sterile saline.
The final pellet was resuspended in 15 ml 2% aminoethylthiouronium bromide (AET)
and incubated at 37°C for 15 min, being shaken every 5 min. AET (Sigma, Poole,
Dorset, UK ) was freshly prepared, syringe filtered (Acrodisc, Gelman Sciences,
Ann Arbor, MI; pore diameter 0.2p.m) and adjusted to pH 8.0 before use. Following
incubation with AET the SRBC were washed four times with sterile saline before being
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resuspended in 10 ml RPMI 1640 supplemented with 0.03% fresh glutamine and 40%
FCS to make a 10% suspension.
1.3 Separation of T lymphocytes
Adherent cells were removed from peripheral blood mononuclear cell preparations by 60
min incubation in 75 cm2 tissue culture flasks at 37°C in 5% CC>2- Cells were
incubated in RPMI 1640 with 0.03% fresh glutamine and 10% FCS at a concentration
of lxlO6 - 2xl06/ml.
Non-adherent cells were counted and adjusted to 3xl07 - 4xl07/ml in RPMI 1640 with
0.03% fresh glutamine and 40% FCS and mixed with an equal volume of freshly
prepared homogeneously resuspended AET-SRBC. One ml aliquots of the suspension
were placed in flat bottomed glass Universals and centrifuged at 145g for 5 min before
being stored at 4°C for 18 hrs. The majority of the supernatant was removed and the
pellet gently resuspended and layered onto a cushion of Ficoll/Hypaque and centrifuged
at 900g for 15 min (50% brake). The interface containing non-rosetted, E~
mononuclear cells (ie. enriched for B lymphocytes) was removed and discarded.
SRBC were removed from the rosetted T lymphocytes in the cell pellet by the addition
of 0.17M ammonium chloride for 10 min on ice. The T lymphocytes were then washed
once with RPMI 1640 with 0.03% fresh glutamine and 5% FCS, then twice with PBS.
1.4 Lymphoblastoid cell lines
RABI2 is an Epstein-Barr virus transformed human B cell line. The RABI2 cell line
was maintained on RPMI 1640, 0.03% fresh glutamine, 5% FCS in 5% C02 at 37°C.
The cells were regularly tested for mycoplasma contamination using the Gen-Probe
mycoplasma T.C. rapid detection system kit (Gen-Probe Incorporated, San Diego,
CA) according to manufacturer's instructions.
The HLAtype of RABI2 was A2,3 B7/27 DR3,4 W52/W53.
2 Lymphocyte proliferation assays
2.1 Mitogen stimulation
Peripheral blood mononuclear cells or T lymphocyte enriched fractions were cultured at
a concentration of 5xl05/ml in 200|xl aliquots in flat bottomed 96-well Microtest II plates
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(Falcon). Cells were cultured in RPMI 1640 supplemented with 0.03% fresh glutamine
and 5% FCS (or in some instances 10% autologous human plasma in place of FCS) and
incubated at 37°C in 5% CO2. Cells were stimulated using phytohaemagglutinin
(PHA) (Wellcome, Beckenham, Kent, UK, reagent grade) at a final concentration of
l-2|xg/ml or pokeweed mitogen (PWM) (Sigma) at a concentration of 0.5p.g/ml.
Assays were performed in the presence of various types of factor VIII, factor IX or
control buffer, included at a range of concentrations.
In some instances, peripheral blood mononuclear cells were incubated overnight in
culture medium containing SNBTS factor VIII at a final concentration of 2iu/ml or
control buffer diluted to the same extent, before being washed three times and
stimulated with 0.5% PHA.
2.2 Antigen stimulation
Peripheral blood mononuclear cells were cultured in RPMI 1640 with 0.03% fresh
glutamine and 10% FCS at a concentration of 2.5xl05/ml in flat bottomed 96-well
plates in 200|jl1 aliquots. Cells were stimulated with tetanus toxoid (Merieux,
Maidenhead, Berkshire, UK) at a final dilution of 1.200.
2.3 One-waymixed lymphocyte reactions
The human B lymphoblastoid cell line RABI2 was used in a one-way mixed lymphocyte
reaction (MLR) to stimulate peripheral blood mononuclear cells. RABI2 cells
resuspended in RPMI 1640 supplemented with 5% FCS and 0.03% fresh glutamine
were exposed to an X-ray dose of 1 000 rads then washed three times in PBS prior to
inclusion in the MLR.
Peripheral blood mononuclear cells and irradiated lymphoblastoid cells were mixed at a
ratio of 2.5:1. 150 p.1 aliquots containing 5xl05 peripheral blood mononuclear cells and
2x10s irradiated lymphoblastoid cells were cultured in 96 v-well plates (Cel-cult).
Cells were cultured in the presence of various types and concentrations of factor VIII
preparations or control buffer.
In some instances, peripheral blood mononuclear cells and lymphoblastoid cells were
preincubated with SNBTS factor VIII at a final concentration of 2iu/ml for 18 hours
before being cultured in a one-waymixed lymphocyte reaction.
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2.4 Labelling cells with 3H-thymidine
Lymphocyte proliferation in response to mitogens, antigens and allogeneic
lymphoblastoid cells was measured by incorporation of 3H-thymidine. Cells were
labelled with l|xCi or 0.5pCi 3H-thymidine (Amersham, Amersham, Bucks, UK) per
well in a 50|xl aliquot of culture medium 18 hours prior to cell harvesting. Replica
plates were labelled at 24 hour intervals for up to 12 days.
2.5 Harvesting cells
Cells were harvested onto glass fibre filter paper using a Skatron Multiple Cell-Culture
harvester (Skatron, AS, Lier, Norway). Discs were dried and counted in Optiscint
"Hi Safe" scintillation fluid (LKB, Loughborogh, UK) in plastic vials using a Tri-carb
liquid scintillation analyzer. Mean 3H-thymidine incorporation was calculated for
duplicate wells. Alternatively plates were harvested and counted using a Matrix 96
direct beta counter (Packard, Ulgersmaweg, Groningen, The Netherlands).
3H-thymidine incorporation for replica cultures did not differ by more than 10%.
2.6 Reproducibility of data
Different factor concentrates of varying purity and protein concentration were compared
simultaneously in lymphocyte proliferation assays using cells from one blood donor.
Samples were performed in duplicate. Assays were performed in general more than
one time, with lymphocytes from more than one blood donor. The number of repeat
assays performed is summarised in Table 2.
3 Human immunodeficiency virus (HIV) infection
3.1 HIV infection of lymphocytes
Peripheral blood mononuclear cells from a HIV seronegative blood donor were infected
with 103 logs of HIV strain SF152 following a two hour incubation period at 37°C.
The infected lymphocytes were then washed three times in RPMI 1640 before being
included in proliferation assays.
3.2 HIV inactivation
A range of chemical agents known to inactivate HIV were tested for their effects on
FACTOR PROLIFERATION BLOOD DONORS NUMBER OF
CONCENTRATE ASSAY TESTED ASSAYS
PERFORMED
SNBTS control PHA 1 1 16
buffer MLR 7 15
SNBTS Z8-6026 PHA 7 1 1
TETANUS 3 3
PWM 2 2
All other batches PHA 2(1-7) 2(1-7)
of SNBTS Z8f MLR 3(1-5) 3(1-6)
BIO PRODUCTS PHA 4(3-5) 4(3-6)
LABORATORY MLR 1(1-2) 1(1-2)
(Elstree)ft
SNBTS S8 MLR 2 2
MONOCLATE PHA 2 2
MONOCLATE-P PHA 3 4
MLR 5 6
PROFILATE PHA 3 3
MLR 1 1
HEMOFIL-M PHA 2 2
MLR 2 2
OCTA-PHARMA PHA 2 2
V.I. 250 MLR 1 1
BIO-TRANSFUSION MLR 2 2
SNBTS FACTOR IX PHA 2 2
MLR 1 1
* Average value for 22 batches screened (range).
ft Average values for 4 batches screened (range).
TABLE 2
Summary table of assays performed. Table 2 details the number of times each
assay was performed giving reproducible results. The number of different blood
donors tested per assay is also indicated.
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3H-thymidine incorporation. Replica samples containing culture medium only, 1X105
PBMC or 1X105 PBMC in 0.1% PHA were cultured in 96-well plates. The cells were
labelled for 18 hours with lp.Ci 3H-thymidine per well, before being incubated for 30
min with either culture medium, 10% TCA, 1% formaldehyde, 2% glutaraldehyde,
20% ethanol or 1% paraformaldehyde (final dilutions). The cells were then harvested
and 3H-thymidine incorporation was assessed by conventional liquid scintillation
counting.
3.3 HIV infected lymphocyte proliferation assays
HIV infected or mock infected lymphocytes were stimulated with irradiated
lymphoblastoid cells as outlined above. Thirty minutes prior to harvesting
paraformaldehyde was added to each well to a final concentration of 1 %, in order to
inactivate HIV present. Cell cultures were harvested onto glass fibre filters using a
Skatron Multiple Cell-Culture Harvester and 3H-thymidine incorporation measured by
liquid scintillation counting .
3.4 Viral quantification
Virus replication was assessed by measuring p24 antigen production in culture
supernatants. Cell culture supernatants from duplicate wells were harvested by
centrifugation at 24 hour intervals post infection. Supernatants were stored at -20°C
until assayed for p24 levels.
HIV p24 antigen was detected using the Coulter HIV p24 Ag enzyme immunoassay
(Coulter Corporation, Hialeah, FL), according to the manufacturer's instructions.
Briefly, cell culture supernatants to be tested were added to microwells precoated with a
murine monoclonal antibody specific for HIV core antigen. If present, antigen
complexed to the antibody-coated microwells. The bound antigen was detected by
biotinylated antibodies to HIV p24, which reacted with conjugated
streptavidin-horseradish peroxidase. Colour developed from the reaction of the
peroxidase with hydrogen peroxide in the presence of tetramethylbenzidine substrate.
The reaction was terminated by Coulter stopping reagent. The amount of HIV p24
antigen present in the cell culture supernatant was proportional to the intensity of the
colour developed. Colour change was measured at a wavelength of 450 nm using a




Peripheral blood mononuclear cells were isolated from defibrinated human buffy coat
donations and cultured at a concentration of lxl06 - 2xl06/ml in RPMI 1640
supplemented with 0.03% fresh glutamine, 5% FCS and 1% PHA (Wellcome, reagent
grade). Cell cultures were incubated for 24 hours at 37°C in 5% CO^ before
supernatants were harvested by centrifugation. The conditioned medium was then
sterile filtered and frozen or stored at 4°C until required.
4.2 Maintaining CTLL-2 cells
Interleukin-2 (IL2) dependent CTLL-2 cells (Gillis and Smith, 1977) obtained from J
Simmonds, were maintained on 50% conditioned medium and 50% RPMI 1640
containing 0.03% fresh glutamine and 5% FCS. Cultures were incubated in 5% C02 at
37°C in 25cm2 tissue culture flasks. Cells were fed every three days and split in a ratio
of 1.10.
4.3 Supernatants tested for IL2 activity
2X106 peripheral blood mononuclear cells were cultured in 1ml aliquots in 48-well
plates (Costar, Cambridge, MA) in RPMI 1640 supplemented with 5% FCS, lu/ml
heparin (Evans Biologicals Ltd, Liverpool, UK) and 0.03% fresh glutamine. The
cells were stimulated with 1 % PHA (Wellcome, reagent grade) and incubated in the
presence or absence of factor VIII at a final dilution of liu/ml. Replica wells were
harvested by centrifugation at 24 hour intervals and the supernatants stored at -20°C
until assayed for IL2 activity. Non-stimulated control wells containing culture medium
or factor VIII were also included.
4.4 IL2 bioassay
Supernatants to be assayed for IL2 activity were harvested by centrifugation and stored
at -20°C until required. CTLL-2 cells were fed 48 hours prior to inclusion in the IL2
bioassay. CTLL-2 cells were washed twice in PBS, then counted and adjusted to
lxl0s/ml in RPMI 1640 with 0.03% fresh glutamine and 5% FCS. 1 OOpul of the cell
suspension was added to lOOptl aliquots of serial doubling dilutions of the test
supernatant or standard recombinant IL2 (British Bio-technology Ltd, Oxford, UK) in
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culture medium in flat-bottomed 96-well plates (Falcon). Cells were incubated for 24
hours at 37°C in 5% CO2 before being pulsed with 3H-thymidine. 0.5[tCi
3H-thymidine (Amersham) per well was added 5 hours prior to cell harvesting and
counting with the Matrix 96 direct beta counter (Packard).
5 Flow cytometry
5.1 Indirect immunofluorescence
Prior to staining for analysis, cell viability was estimated using 0.5% nigrosin dye
exclusion. Cells able to exclude the nigrosin dye were scored as viable. To remove
debris peripheral blood mononuclear cells were layered onto Ficoll/Hypaque and
centrifuged for 15 min at 900g (50% brake). Viable cells at the interface were removed
and washed twice with PBS before being stained for flow cytometry. Lymphoblastoid
cells of poor viability were removed following centrifugation over a Hypaque cushion
(Sigma) at 550g for 15 mins (75% brake). Viable cells at the interface were removed
and washed two times with PBS before use. Only cell preparations of greater than 80%
viability were stained for analysis.
Cells were washed two times in PBS containing 1% bovine serum albumin and 0.02%
azide (PBS. BSA). 5X105 - 1X106 cells were incubated with 50p.l or 20^1 of the
mouse monoclonal antibody of interest for 45 min. Cells were washed twice with
PBS. BSA and incubated with lOOftl of fluorescein isothiocyanate (FITC) conjugated
anti-mouse immunoglobulin (Sigma F2883) at a final dilution of 1.100 for 30 min, in
darkness. Cells were washed two times in PBS. BSA before being fixed in 400p.l of
1% formaldehyde in PBS. Fixed cells were stored at 4°C in darkness for up to 72
hours before analysis. Cells were analysed using a bench top flow cytometer
(FACScan, Becton-Dickenson, Mountain View, CA) equipped with an argon-ion laser
emitting light at a fixed wavelength of 488nm. Fluorescence output signals were
collected in logarithmic mode. Light scatter signals were collected in linear mode.
5.2 Expression of cell surface activation markers
Peripheral blood mononuclear cells were rosetted overnight with AET-treated sheep red
blood cells and the E+ T-enriched cells isolated in this manner were incubated inRPMI
1640, 0.03% fresh glutamine and 5% FCS. T-enriched cells were cultured at 37°C in
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5% CO2 at a final concentration of lxl06/ml and stimulated with 0.2% PHA. Cells
were cultured in the presence of a variety of factor VIII preparations, present at a range
of concentrations, and analysed for the expression of cell surface markers indicative of
activation.
Replica cell cultures were therefore labelled with monoclonal antibodies specific for
HLA.DR (Becton Dickinson, clone L243), CD 71, the transferrin receptor (Becton
Dickinson, clone L01.1) and CD 25, the IL2 receptor (Becton Dickinson, clone 2A3).
Control cell cultures were labelled with FITC only and a mouse isotypic control
antibody specific for alpha foeto protein, in order to determine the degree of
non-specific staining. The expression of CD 44, a cell surface marker whose
expression is not normally altered during cell activation, was also investigated using a
monoclonal antibody specific for CD 44 (The Binding Site Ltd, Birmingham, UK;
clone BU 52) in order to ascertain whether effects of some factor VIII preparations were
restricted to the expression of activation markers. CD 44 is a transmembrane protein
thought to function as a homing receptor.
The percentage of cells expressing cell surface activation markers in the presence or
absence of 2iu/ml SNBTS factor VIII was compared using a paired f-test.
5.3 Expression of HLA.DR
The effect of factorVIII concentrate on HLA. DR expression in lymphoblastoid cells
was investigated. Irradiated RABI2 cells were incubated in 1ml aliquots at lX106/ml in
RPMI 1640, 5% FCS, 0.03% fresh glutamine, lu/ml heparin and 2iu/ml SNBTS
factor VIII. Control cultures did not contain factor VIII preparations. Lymphoblastoid
cells were collected at 24 hour intervals following flotation over a Hypaque cushion
(Sigma) and stained as described above for the expression of HLA.DR (Becton
Dickinson, clone L243).
5.4 Two colour flow cytometry
Cells responding to irradiated lymphoblastoid B cells were characterized using two
colour flow cytometry. 6.6X105 peripheral blood mononuclear cells were cultured
with 2.6X1 05 irradiated RABI2lymphoblastoid cells in 2ml aliquots in round-bottomed
tubes (Falcon). Cells were incubated in the presence or absence of 2iu/ml SNBTS
factor VIII in RPMI 1640 with 5% FCS, 0.03% fresh glutamine and lu/ml heparin.
Cultures were maintained in 5% C02 at 37°C for 5 days before being characterized by
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two colour flow cytometry.
The mixed cell populations were resuspended and layered onto Ficoll/Hypaque, then
spun at 900g for 15 min (95% brake) to remove RABI2 cells and debris. The viable
responding cells at the interface were removed and washed two times in PBS. BSA
before being stained.
5X105 cells were incubated with monoclonal antibodies specific for CD 71 (Becton
Dickinson, clone L01.1), CD 25 (Becton Dickinson, clone 2A3), HLA.DR (Becton
Dickinson, clone L243), CD w49 (Serotec, Bicester, Oxon, UK; GI 5), CD 54
(Serotec, 84 HIO), CD 45R0 (UCHL1), CD 3 (Serotec, IOT3) and CD 19 (3rd
Leucocyte typing workshop, BU 12) for 30 min at room temperature. The cells were
then washed two times and incubated for 30 min with 1 OOpl of anti-mouse FITC
conjugate (Sigma F2883) at a dilution of 1.100, in the dark. Alternatively 5X105
unlabelled cells were incubated for 30 min with a monoclonal antibody specific for CD
29 (Coulter, 4B4) which was directly conjugated with FITC. The cells were washed
two times before remaining binding sites on the anti-mouse conjugate were blocked
using 50|il of normal mouse serum at a 1.10 dilution. Following a 5 min incubation
period 10p.l of phycoerythrin labelled monoclonal antibody specific for CD4 (Serotec,
Edu-2) or CD8 (Serotec, UCH-T4) were added for a further 30 min incubation period
in the dark. The cells were then washed twice in PBS. BSA before being fixed in 400p.l




A number of commercial and non-commercial factor VIII preparations were included
for study. Various batches of Z8 factor VIII, manufactured by the Scottish National
Blood Transfusion Service (SNBTS) Protein Fractionation Centre (21 Ellen's Glen
Road, Edinburgh) were compared in a number of functional assays. SNBTS Z8
concentrate is manufactured from large volumes of frozen human plasma using a method
based on extraction from controlled cryoglobulin precipitate. All plasma donations are
screened for evidence of HIV or hepatitis virus infection prior to inclusion in the
manufacturing process. In addition SNBTS Z8 is heated to 80 °C for 72 hours in the
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dried state. Properties of batches of SNBTS Z8 factor VIII concentrate studied are
listed in Appendix I. Buffer, equivalent to the final buffer in which Z8 factor VIII is
administered was included for control purposes.
Assays were also performed on 8Y factor VIII manufactured by the Bio Products
Laboratory (Plasma Fractionation Laboratory, Churchill Hospital, Oxford),
Octapharma V.I.250 (Octapharma, Dusseldorf, Germany), Profilate Heat-Treated
(Alpha Therapeutic Corporation, Los Angeles, CA), Bio-transfusion high purity factor
VIII concentrate (Bio-transfusion, Lille, France) and monoclonal antibody purified
products Monoclate (Armour Pharmaceutical Company, Kankakee, Illinois),
Monoclate-P (Armour Pharmaceutical Company) and Hemofil-M (Baxter Healthcare
Corporation, Glendale, CA).
BPL 8Y factor VIII is a lyophilised high purity concentrate prepared from large pool
fresh frozen plasma. The concentrate is manufactured from volunteer plasma donations
collected throughout England and Wales. Plasma included in BPL 8Y factor VIII is
screened for antibodies to hepatitis B surface antigen and HIV. After lyophilisation 8Y
factor VIII is heat treated for 72 hours at 80 °C.
Bio-transfusion high purity factor VIII concentrate is prepared from plasma by
cryoprecipitation followed by ion exchange chromatography. The high purity
concentrate produced contains few contaminating proteins and has a factor VIII activity
of 42.5-9.5 iu/ml. The concentrate is solvent/detergent treated for virus inactivation.
Monoclate factor VIII concentrate is prepared from pooled human plasma collected from
paid donors. Factor VIII purification is achieved by immuno-affinity chromatography
using mouse monoclonal antibodies raised against human von Willebrand factor antigen
(F VIII:R). The final product is stabilised by the addition of human albumin and heat
treated for 30 hours at 60 °C. Monoclate-P high purity factor VIII concentrate is
prepared in a similar manner but pasteurized, ie. heated to 60 °C for 10 hours in
aqueous solution.
Hemofil-M factor VIII is prepared from pooled human plasma by immuno-affinity
chromatography using a mouse monoclonal antibody specific for human factor VIII:C.
The preparation is further purified by ion exchange chromatography. Human albumin
is included in the final product as a protein stabiliser. The preparation is treated with
organic solvent and detergent (tri(n-butyl) phosphate and Triton X-100) as a virus
inactivation step and lyophilised.
All concentrates were stored and reconstituted according to the manufacturer's
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instructions before use in vitro. Characteristics of commercial factor VIII preparations
are listed in Appendix II.
A newly developed prototype higher purity factor VIII concentrate termed S8 and factor
IX concentrate manufactured by the Scottish National Blood Transfusion Service were
included in some lymphocyte proliferation assays. The manufacturing process for
SNBTS prototype high purity S8 factor VIII concentrate has not been published.
SNBTS factor IX concentrate (Defix) is purified from fresh frozen plasma using DEAE
cellulose chromatography. Characteristics of SNBTS Z8, SNBTS S8 and SNBTS
factor IX concentrates are listed in Appendix III.
6.2 Tissue culture
RPMI 1640 culture medium was supplemented with lu/ml heparin in addition to 0.03%
fresh glutamine and 5% FCS in the presence of factor VIII, following complications of
clot formation. Reconstituted factor VIII concentrate was diluted with growth medium
and included in assays according to factor VIII activity in iu/ml as stated by the
manufacturer. The range of factor VIII activity covered in vitro (0.05 - 2iu/ml) was
chosen to reflect factor VIII levels in haemophilia patients following factor VIII
replacement therapy.
6.3 Cell Viability
The effect of SNBTS factor VIII on peripheral blood mononuclear cell and irradiated
lymphoblastoid B cell viability was investigated by 0.5% nigrosin dye exclusion.
1X106 cells were incubated in 48-well tissue culture plates (Costar) in replica 1ml
aliquots in the presence or absence of liu/ml SNBTS factor VIII. Culture medium
comprised RPMI 1640, 5% FCS, 0.03% fresh glutamine and liu/ml heparin. Cells
were incubated at 37°C in 5% C02 and viability estimated at 24 hour intervals.
200 cells were counted four times and the mean percentage of nigrosin positive cells was
calculated. Cell viability in the presence or absence of SNBTS factor VIII was
compared using a paired f-test. P values of <0.01 were considered significant.
6.4 Defibrinating SNBTS factor VIII
SNBTS factor VIII was reconstituted and defibrinated using sterile orange sticks
following the addition of 200|jl1 bovine thrombin (Pentex). Fresh orange sticks were
used to gently stir the factor VIII solution until all fibrin clots were removed.
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Following defibrination the volume of factor VIII was generally reduced from 20mls to
approximately 5mls.
6.5 Physical manipulation of SNBTS factor VIII
Freshly reconstituted and freeze-thawed factor VIII from the same batch were compared
in lymphocyte proliferation assays. Similarly, the in vitro characteristics of filtered
and non-filtered factor VIII were compared. Freshly reconstituted factor VIII was
syringe filtered through an Acrodisc membrane of 0.2|tm pore diameter (Gelman
Sciences) before being included in proliferation assays.
A number of ultrafiltration devices of various molecular weight cut off values were used
to crudely fractionate factor VIII into a series of broad molecular weight bands.
Defibrinated factor VIII was successively filtered through Centriprep concentrators
(Amicon, Danvers, Massachusetts) with molecular weight cut off values of 100,000
Da, 30,000 Da and 10,000 Da according to the manufacturer's instructions. Fractions
obtained in this manner were included in lymphocyte proliferation assays in vitro.
6.6 Selective protein depletion
In preliminary experiments, specific protein contaminants present in SNBTS factor VIII
were targeted for removal by immunomagnetic isolation. Uniform magnetic
polystyrene beads were coated with monoclonal antibodies, in an attempt to deplete
factor VIII preparations of factor VHI/von Willebrand factor, fibronectin and HLA. DR
proteins.
Approximately 4X107 Dynabeads M-450 (lOOpl), precoated with goat anti-mouse IgG
(Dynal, Oslo, Norway) were resuspended and incubated with 6pg of mouse
monoclonal antibody specific for factor Vlllc/von Willebrand factor (Chemicon,
Temecula, CA; MAB038), fibronectin (Chemicon MAB122) or HLA.DR (Becton
Dickinson Clone L243). The beads were rotated for even mixing for 4 hours at 4°C.
The Dynabeads were collected with a Dynal Magnetic Particle Concentrator (Dynal MPC
6) and the supernatant discarded. The coated beads were resuspended in PBS
containing 0.1% BSA and washed four times for 30 min at 4°C in PBS containing 1%
FCS. The beads were collected between washes using the Dynal MPC 6.
Coated beads were incubated with 100|xl of SNBTS facor VIII (Z8-92490) for 30 min at
4°C using rotation for evenmixing. The depleted factor VIII preparations were then
removed and stored overnight at room temperature before being assayed in a standard
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one-way mixed lymphocyte reaction, as described above.
7 Fibronectin
7.1 One-way mixed lymphocyte reactions
Purified human fibronectin (Chemicon, tissue culture grade) was substituted for factor
VIII concentrate in mixed lymphocyte reactions, as described above. Fibronectin was
included at concentrations representative of fibronectin content in intermediate purity
SNBTS factor VIII preparations (final concentration range 21(Jig/ml-425|a.g/ml).
8 Polyacrylamide gel electrophoresis
8.1 Sample preparation
Factor VIII preparations were reconstituted according to manufacturers' instructions and
added directly to 4X sample buffer. Alternatively, concentrate buffer was exchanged
for lOmM Tris-HCl prior to the addition of sample buffer. Biogel PD6 (Bio-Rad
Laboratories, Richmond, CA) was swollen in 20mM Tris-HCl buffer pH 7.5 and
stored at 4°C until required. Micro-columns containing 500|il of Biogel PD6 were
loaded with lOmM Tris-HCl and centrifuged at 300g for 30 sec at 95% brake two times
to allow the column to equilibrate. 100p.l of factor VIII was then loaded, centrifuged at
300g for 30 sec at 95% brake through the column and collected into a receptacle below.
Samples were loaded in IX SDS sample buffer at a protein concentration of
approximately 2mg/ml (4X sample buffer comprised 0.2M Tris-HCl pH 6.5, 20%
SDS, 8mM EDTA, 40% glycerol and 0.016% bromophenol blue). 50p.g and 100|xg
of protein were loaded onto each track for silver and Coomassie Blue staining
respectively. Dithiothreitol (DTT) was added to lOmM final concentration for reduced
samples. Samples were boiled for 2 min and centrifuged for 4 min in an Eppendorf
microcentrifuge prior to sample loading.
8.2 Polyacrylamide gels
Electrophoresis under denaturing conditions was performed using slab gels in the
discontinuous buffer system of Laemmli (1970).
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Factor VIII samples were electrophoresed through 7% polyacrylamide gels. The
separating gel mix comprised 7% acrylamide, 0.187% NN1-methylene bis-acrylamide,
0.375M Tris-HCl pH 8.8 and 0.1% SDS. 30ml of separating gel mix was
polymerised following the addition of 48^1 TEMED and 150jjl1 10% ammonium
persulphate.
The stacking gel mix comprised 4.95% acrylamide, 0.132% NN'-methylene
bis-acrylamide, 0.125M Tris-HCl pH 6.5, and 0.1% SDS. 10ml of stacking gel mix
was polymerised following the addition of 24|a.l TEMED and 75|a.l 10% ammonium
persulphate.
Gels were electrophoresed overnight in electrode buffer containing 0.0496M Tris-base,
0.384M glycine and 0.1% SDS.
8.3 Gel staining
(i) Coomassie blue staining
Gels to be stained using Coomassie blue were fixed for 10 min in 10% acetic acid, 20%
methanol before being stained for 5 min with 0.125% Coomassie blue R in 50%
methanol, 7.5% acetic acid. Gels were destained overnight by soaking in 7% acetic
acid, 10% methanol. Stained gels were rinsed and stored in distilled water.
(ii) Silver staining
Gels to be silver stained were fixed at room temperature in a shaking waterbath for 20
min with 20% methanol, 10% acetic acid. The gel was soaked in 50% methanol for 1
hour and rinsed with distilled water for 5 min. This step was repeated two more times
before the gel was stained for 15 min at room temperature. The stain solution
comprised 0.4% silver nitrate, 0.0756% NaOH, and 0.2072M ammonium hydroxide.
The stain was prepared by adding the silver nitrate dropwise to the NaOH and
ammonium hydroxide whilst stirring constantly. Following staining, the stain was
discarded and the gel rinsed for 5 min with distilled water. The gel was soaked in
0.005% citric acid, 0.0005% formaldehyde (38% stock) developer solution for 5-15
min to allow visualisation of protein bands. The developer was stopped by the addition




1 Effects of factorVIII concentrate on lymphocyte proliferation following stimulation
with phytohaemagglutinin
1.1 3H-thymidine incorporation
Seventeen of eighteen batches of SNBTS Z8 factor VIII concentrate inhibited
lymphocyte proliferation in a dose-dependent manner (Fig 1). When present at a
concentration of 2iu/ml, factor VIII reduced 3H-thymidine incorporation by 85% and
delayed the response by 72 hours.
One batch of SNBTS factor VIII (Z8-6026) inhibited lymphocyte proliferation at high
concentrations, but enhanced lymphocyte proliferation when present over a lower dose
range (Fig 2).
Buffer used in the manufacture of SNBTS factor VIII delayed proliferation when
present at a high concentration only (Fig 3).
Four batches of BPL intermediate purity factor VIII concentrate were tested and found to
inhibit lymphocyte proliferation in a dose-dependent fashion (Fig 4).
The high purity factor VIII concentrate Profilate inhibited lymphocyte proliferation when
present at 2iu/ml, but not at lower concentrations (Fig 5).
High purity Octa-Pharma V.I. 250 did not inhibit lymphocyte proliferation over a range
of dilutions tested (Fig 6).
Similarly, monoclonal antibody purified factor VIII preparations Hemofil-M,
Monoclate and Monoclate-P had no effect on 3H-thymidine incorporation (Figs 7, 8,
9).








PHA 2ng/ml Factor VIII 2iu/ml
PHA 2ng/ml Factor VIII 1iu/ml
PHA 2Mg/ml Factor VIII 0.5iu/ml
PHA 2tig/ml Factor VIII 0.25iu/ml






Dose dependent inhibition of lymphocyte proliferation by SNBTS Z8 factor
VIII. PBMC were stimulated with PHA at 2 pg/ml. Total protein added per




PHA 2ng/ml Factor VIII 2 iu/ml
PHA 2jjg/ml Factor VIII 1 iu/ml
♦PHA 2yg/ml Factor VIII 0.5 iu/ml
-a-PHA 2yg/ml Factor VIII 0.25 iu/ml




Immunomodulatory effect of SNBTS batch Z8-6026 factor VIII concentrate on
lymphocyte proliferation in response to 2 n-g/ml PHA. Total protein added per













PHA 2ng/ml Buffer 1/160 dilution
DAYS INCUBATION
Fig 3
Control buffer used in the manufacture of SNBTS factor VIII concentrate delayed






♦PHA 1 Mg/rnl Factor VIII 2iu/m!
♦PHA 1 Mg/ml Factor VIII 0.5iu/ml
♦PHA 1 Mg/ml Factor VIII 0.25iu/ml
♦PHA 1 Mg/ml Factor VIII 0.1 25iu/ml




Dose dependent inhibition of lymphocyte proliferation in response to 1 pg/ml PHA
in the presence of Bio Products Laboratory factor VIII. Total protein included per




-B- PHA Ipg/ml PROFILATE 2iu/m1
-©- PHA 1 tig/ml PROFILATE 0.5iu/ml
PHA 1 Mg/m! PROFILATE 0.25iu/ml




Effect of high purity Profilate factor VIII concentrate on lymphocyte proliferation
in response to PHA stimulation. Total protein included per assay ranged from
0.03 mg/ml to 0.45 mg/ml.
OCTA PHARMA V.I. 250
-a-PBNC
-♦-PHA 1 tig/ml
♦ PHA 1 Mg/ml 0CTA V.I . 250 2iu/ml
-o-PHA 1 Mg/ml 0CTA V.I . 250 0.5iu/ml
♦PHA 1 Mg/ml OCTA V.I . 250 E\=3inCNo
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DAYS INCUBATION
Fig 6
The proliferative response to PHA was not affected by high purity Octa-Pharma
V.I. 250 factor VIII over a range of concentrations. Total protein included per




♦ PHA lug/ml HEMOFIL-M 0.5iu/ml
-o-PHA 1 jig/ml HEMOFIL-M 0.25iu/ml
♦PHA 1 Mg/ml HEMOFIL-M 0.125iu/ml






Monoclonal antibody purified Hemofil-M factor VIII concentrate had no effect on




♦ PHA lug/ml MONOCLATE 2iu/ml
-o-PHA 1 jjg/ml MONOCLATE 0.5iu/ml
♦ PHA 1 Mg/ml MONOCLATE 0.125iu/ml




Effect of monoclonal antibody purified Monoclate factor VIII on PHA stimulation





-m- PHA 1 Mg/ml MONOCLATE-P 2iu/ml
-o- PHA 1 Mg/ml MONOCLATE-P 1iu/ml
-m- PHA 1 Mg/ml MONOCLATE-P 0.5iu/ml




The proliferative response to PHA was not affected by pasteurized monoclonal
antibody purified Monoclate-P factor VIII. Total protein included per assay




■•"PHA lug/ml Factor IX 2iu/ml
-^"PHA Ipg/ml Factor IX liu/ml
♦PHA 1yg/ml Factor IX 0.5iu/ml





SNBTS factor IX inhibited and delayed PBMC proliferation in response to PHA in
a dose dependent fashion. Total protein included per assay ranged from 0.04
mg/ml to 0.88 mg/ml.
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1.2 Cell surface activation marker expression
I have confirmed the observation by Hay et al (1990) that factor VIII concentrate altered
lymphocyte activation marker expression in \itro.
Factor VIII concentrate or control buffer were incubated with mononuclear cell
populations enriched for T cells and stimulated with PHA.
Flow cytometric analysis showed that both SNBTS factor VIII concentrate and buffer
caused a reduction in the percentage of cells expressing CD25 and CD71 in a
dose-related fashion. Neither concentrate nor buffer altered the expression of CD44 or
HLA.DR (Figs 11, 12).
The expression of CD25 in the presence of 2iu/ml factor VIII and CD71 in the presence
of control buffer at a dilution of 1/5.75 was significantly reduced (P<0.05).
All other differences failed to reach significance.
The percentage of cells analysed staining positive for CD5, CD 14 and CD 19 were 97%,
0.4% and 1.5% respectively.
Incubation of Monoclate-P with T-enriched cells stimulated with PHA had no effect on
activation marker expression (Fig 13).
In a comparative study, SNBTS S8 prototype higher purity factor VIII concentrate was
found to reduce the percentage of cells expressing CD25 and CD71 to the same extent as
SNBTS intermediate purity factor VIII. The percentage of cells expressing activation
markers was reduced to a lesser extent by control buffer (Figs 14, 15, 16).
The expression of CD25 in the presence of 2iu/ml SNBTS Z8, 2iu/ml SNBTS S8 or
1/5.75 control buffer was significantly reduced (P<0.05). All other differences failed
to reach significance.
1.3 IL2 production
I have confirmed the observation by Thorpe et al (1989) that factor VIII concentrate
altered IL2 secretion by peripheral blood mononuclear cells in vitro.
Levels of IL2 were assayed by measuring the proliferative response of IL2 dependent










Percentage of cells staining positive for activation markers CD 25, CD 71 and
HLA.DR following PHA stimulation in the presence of SNBTS Z8 factor VIII.










The effect of control buffer on activation marker expression following stimulation











The expression of activation markers CD 25, CD 71 and HLA.DR following PHA
stimulation was not affected by the presence of Monoclate-P factor VIII









Effect of SNBTS Z8 factor VIII on activation marker expression following PHA









Effect of prototype high purity SNBTS S8 factor VIII concentrate on activation
marker expression following PHA stimulation. Total protein included per assay










Effect of SNBTS control buffer on activation marker expression following PHA
stimulation.
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48 hours post stimulation in the presence or absence of liu/ml SNBTS factor VIII.
Neither factor VIII nor PHA affected 3H-thymidine incorporation in response to
recombinant IL2. Peripheral blood mononuclear cells stimulated with PHA produced
lower levels of IL2 in the presence of factor VIII concentrate (Fig 17). At 24 hours
post stimulation IL2 secretion was reduced approximately two fold in the presence of
liu/ml SNBTS factor VIII.
Values were converted to a percentage of the maximum counts per minute obtained and
IL2 values calculated (Fig 18, Table 3). Points on the dilution axis corresponding to
50% of the maximum counts perminute are designated lunit of IL2 activity.
1.4 Preincubation of SNBTS Z8 factor VIII with peripheral blood mononuclear cells
Significant inhibition of lymphocyte proliferation following PHA stimulation only
occurred if factor VIII concentrate was present throughout the culture period.
Peripheral blood mononuclear cells incubated overnight with 2iu/ml SNBTS factor VIII
responded normally to PHA (Fig 19).
1.5 Filtered SNBTS factor VIII concentrate
In a comparative series, factor VIII filtered through a membrane (0.2^m pore diameter)
behaved identically to fresh concentrate from the same batch. 100% and 50% inhibition
was observed at concentrations of 5iu/ml (1/2.4 dilution) and 2iu/ml (1/6 dilution)
respectively. Control buffer partially reduced and delayed the proliferation response
when present at a high concentration (Fig 20, 21, 22).
2 Effect of SNBTS factorVIII batch Z8-6026 on lymphocyte proliferation following
stimulation with tetanus toxoid
SNBTS factor VIII batch Z8-6026 inhibited the proliferation response to the recall
antigen tetanus toxoid completely when present at 2iu/ml. Proliferation was partially
reduced when the concentrate was included at a concentration of liu/ml. In contrast,
the response to tetanus toxoid was markedly enhanced by this particular batch of






-■-24 hours Factor VIII 1 iu/ml
48 hours




Proliferative response of IL2 dependent CTLL-2 cells to culture supernatants







-H- 24 hours Factor VIII 1 iu/ml
-0- 48 hours
-m- 48 hours Factor VIII 1 iu/ml
LOG 2 DILUTION
Fig 18
Values obtained in CTLL-2 bioassay converted to percentage of maximum counts
per minute. Points on the dilution axis corresponding to 50% of the maximum








24 hours 24.4 21.11
24 hours F VIII 23.3 9.85
48 hours 22.8 6.96
48 hours F VIII <211 <2.14
Table 3
IL2 production following PHA stimulation in the presence or absence of 1 iu/ml
SNBTS Z8 factorVIII concentrate. IL2 production was assayed at 24 hours
and 48 hours post stimulation. Values for 3H-thymidine incorporation were
converted to a percentage of the maximum counts perminute obtained. Points on
the dilution axis corresponding to 50% of the maximum counts per minute are
designated 1 unit of IL2 activity.
PREINCUBATION OF SNBTS FACTOR VIII (Z8-92450) WITH
PERIPHERAL BLOOD MONONUCLEAR CELLS.
-o- PBMC
PBMC incubated with Factor VIII (2iu/ml) overnight
-•-PBMC, PHA 1 jjg/ml
PBMC incubated with Factor VIII (2iu/mi) overnight, PHA 1 jjg/ml




Effect of preincubation of PBMC with factor VIII concentrate prior to activation.
Inhibition of lymphocyte proliferation in response to PHA stimulation was





PHA 2Mg/ml Factor VIII (fresh) 5iu/ml
-®- PHA 2ug/ml Factor VIII (fresh) 2iu/ml
DAYS INCUBATION
Fig 20






PHA 2yg/ml Factor VIII (filtered) 1/2.4 dilution
-o- PHA 2(ig/ml Factor VIII (filtered) 1/6 dilution
DAYS INCUBATION
Fig 21
Effect of SNBTS factor VIII filtered through a 0.2 pm pore sized membrane on




PHA 2|jg/ml Buffer 1/2.4 dilution






























Effect of SNBTS control buffer on lymphocyte proliferation in response to PHA at




-B- Tetanus toxoid 1/200 Factor VIII 2iu/ml
-0- Tetanus toxoid 1/200 Factor VIII 1iu/ml
Hh Tetanus toxoid 1/200 Factor VIII 0.5iu/m1
Tetanus toxoid 1/200 Factor VIII 0.25iu/ml




Lymphocyte proliferation in the presence of SNBTS Z8-6026
following stimulation with the recall antigen tetanus toxoid.
Total protein included per assay ranged from 0.28 mg/ml to 4.41
mg/ml.
55
3 Effect of SNBTS factor VIII batch Z8-6026 on lymphocyte proliferation following
stimulation with pokeweed mitogen
Lymphocyte proliferation in response to PWM was completely inhibited by SNBTS
factor VIII batch Z8-6026 when present at 4iu/ml. Over a lower range of
concentrations this batch of concentrate enhanced 3H-thymidine incorporation in
response to PWM stimulation (Fig 24).
In the absence of mitogen or antigen stimulation SNBTS factor VIII batch Z8-6026 did
not stimulate peripheral blood mononuclear cells.
4 Effect of factor VIII concentrate on lymphocyte proliferation following stimulation
with irradiated allogeneic lymphoblastoid cells
4.1 3H-thymidine incorporation
Seven of seven batches of SNBTS Z8 factor VIII concentrate tested enhanced
lymphocyte proliferation in response to irradiated allogeneic lymphoblastoid cells in a
weak one-way mixed lymphocyte reaction (Fig 25).
Peripheral blood mononuclear cells did not respond to SNBTS intermediate purity factor
VIII concentrate in the absence of allogeneic stimulator cells.
In a comparative series SNBTS Z8 and SNBTS S8 (prototype higher purity factor VIII)
enhanced lymphocyte proliferation in a weak one-way mixed lymphocyte reaction (Fig
26, 27).
In contrast, SNBTS control buffer, high purity (Bio-transfusion) and monoclonal
antibody purified (Monoclate-P) factor VIII preparations did not alter the response to
allogeneic stimulator cells (Fig 28, 29, 30).
Factor VIII concentrates were included at equivalent dilutions of factor VIII activity.
High purity concentrates Profilate and Octa-Pharma V.I.250 caused little or no enhanced







PWM 1/2000 Factor VIII 4iu/ml
PWM 1/2000 Factor VIII 2iu/ml
PWM 1/2000 Factor VIII 1iu/ml








Effect of SNBTS factor VIII batch Z8-6026 on PBMC proliferation following






PBMC LCL Factor VIII 2iu/ml
-a- PBMC LCL Factor VIII 1 iu/ml
PBMC LCL Factor VIII 0,25iu/ml




Enhanced lymphocyte proliferation in the presence of SNBTS Z8 factor VIII
concentrate. PBMC were stimulated with irradiated allogeneic lymphoblastoid
cells in the presence of various concentrations of factor VIII. Total protein
included per assay ranged from 0.04 mg/ml to 4.18 mg/ml.
SNBTS Z8-92520





Effect of SNBTS Z8 factor VIII on lymphocyte proliferation in a weak one way
mixed lymphocyte reaction. Enhanced proliferation was evident when factor VIII
was included at 0.1 iu/ml to 1.0 iu/ml (total protein 0.22 mg/ml to 2.18 mg/ml).
SNBTS S8-0006


















Effect of prototype high purity SNBTS S8 factor VIII concentrate on lymphocyte
proliferation in response to irradiated allogeneic stimulator cells. Total protein






-o- PBMCICL BUFFER 1/10
* PBMCICL BUFFER 1/20




The proliferative response to allogeneic stimulator cells was not affected by the
presence of SNBTS control buffer. Dilutions of buffer included were equivalent
to the dilutions of SNBTS factor VIII concentrate assayed.
BIO-TRANSFUSION





PBMC1CL Factor VIII 1 iu/ml
£Z -m- PBMC :LCL Factor VIII 0.5iu/ml





High purity Bio-transfusion factor VIII concentrate had no effect on PBMC
proliferation in response to irradiated allogeneic stimulator cells. Total protein
included per assay ranged from 5.6 X 10-4 mg/ml to 5.6 X 10-3 mg/ml.
MONOCLATE-P





-o-PBMClCL Factor VIII 1 iu/ml
PBMC1CL Factor VIII 0.5iu/ml




The proliferative response to allogeneic stimulator cells was not affected by the
presence of monoclonal antibody purified Monoclate-P factor VIII concentrate.













-o- PBMC1CL Factor VIII 2iu/ml
PBMCiCL Factor VIII 0.5iu/ml
-o- PBMCiCL Factor VIII 0.25iu/ml




Effect of high purity Profilate factor VIII concentrate on lymphocyte proliferation
in the mixed lymphocyte reaction. Total protein included per assay ranged from





-0- PBMC1CL Factor VIII 2iu/ml
PBMC1CL Factor VIII 0,5iu/ml
-a- PBMC1CL Factor VIII 0,25iu/ml











Effect of high purity Octa-Pharma V.I. 250 factor VIII concentrate on lymphocyte
proliferation in response to irradiated allogeneic stimulator cells. Total protein
included per assay ranged from 4 X 10-3 mg/ml to 0.4 mg/ml.
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The monoclonal antibody purified factor VIII concentrate, Hemofil-M did not
significantly enhance 3H-thymidine incorporation in response to allogeneic stimulator
cells (Fig 33).
Three of three batches of Bio Products Laboratory 8Y factor VIII concentrate enhanced
lymphocyte proliferation in a weak one-way mixed lymphocyte reaction, but to a lesser
extent than SNBTS intermediate purity factor VIII (Fig 34).
When incubated at high concentrations factor IX concentrate manufactured by the
Scottish National Blood Transfusion Service enhanced lymphocyte proliferation in this
assay system (Fig 35).
5 Characterisation of cells in mixed lymphocyte reactions
Cells proliferating in response to irradiated allogeneic stimulator cells and SNBTS Z8
factor VIII were characterised by flow cytometry.
Proliferating cells included CD 4+ and CD 8+ T lymphocytes. Seven percent of cells
analysed expressed the B cell marker CD 19. Both T cell subsets expressed a range of
cell surface activation markers including CD 71, CD 25 and HLA. DR. A smaller
proportion of T cells expressed CDw 49, an antigen mainly found on platelets and
activated and long-term cultivated T cells. The intercellular adhesionmolecule,
ICAM-1 (CD 54), was expressed on 70% and 49% of CD 4+ and CD 8+ cells
respectively. A large proportion of T cells expressed thememory T cell marker CD
45RO (Table 4).
6 Physical manipulation of SNBTS intermediate purity factorVIII concentrate
6.1 Freezing, filtering and defibrinating factor VIII
Peripheral blood mononuclear cell transformation in response to allogeneic
lymphoblastoid stimulator cells was enhanced in the presence of fresh, freeze-thawed,







-o- PBMC1CL Factor VIII 2iu/ml
PBMC:LCL Factor VIII 1iu/ml






Effect of monoclonal antibody purified Hemofil-M factor VIII concentrate on






-O- PBIiClCL Factor VIII 2iu/ml
HH PBMC1CL Factor VIII 1 iu/ml
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Intermediate purity Bio Products Laboratory factor VIII concentrate enhanced
lymphocyte proliferation in response to irradiated allogeneic stimulator cells
when present at high concentrations. Total protein included per assay ranged









PBMC:LCL Factor IX 2iu/ml
PBMC:LCL Factor IX 1iu/ml
PBMC1CL Factor IX 0.5iu/ml
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Fig 35
Effect of SNBTS factor IX concentrate on lymphocyte proliferation in
the mixed lymphocyte reaction. Total protein included per assay ranged










CD 19 2 1
CD29 74 53
Responding cells were harvested and characterised by two colour flow
cytometry, as described in text, 5 days after establishment of
cultures. PBMC were stimulated with irradiated allogeneic
lymphoblastoid cells in the presence of 2iu/ml SNBTS factor VIII.
Table 4
Characterisation of cells proliferating in response to irradiated allogeneic






PBMC1CL Factor VIII (frozen) 1/5 dilution
PBMC.'LCL Factor VIII (frozen) 1/10 dilution
-o- PBMC1CL Factor VIII (frozen) 1/20 dilution
PBMC1CL Factor VIII (frozen) 1/100 dilution
DAYS INCUBATION
Fig 36
Freeze-thawing has no effect on the co-mitogenic properties of SNBTS Z8 factor







-©- PBhC LCL Factor VIII (filtered)
PBhC LCL Factor VIII (filtered)
-O- PBhC LCL Factor VIII (filtered)
-4r PBhC LCL Factor VIII (filtered)
1/5.75 dilution





The effect of syringe filtering (0.2 |xm pore size) SNBTS Z8 factor VIII prior to
inclusion in the one way mixed lymphocyte reaction. Enhanced lymphocyte
proliferaton in response to irradiated allogeneic cells occurs in the presence of






-o- PBMC1CL Factor VIII (defibrinated) 1/5.75 dilution
-9- PBMC1CL Factor VIII (defibrinated) 1/11.5 dilution
-a- PBMC1CL Factor VIII (defibrinated) 1/23 dilution
PBMC1CL Factor VIII (defibrinated) 1/115 dilution
DAYS INCUBATION
Fig 38
Enhanced lymphocyte proliferation in response to irradiated
allogeneic stimulator cells in the presence of defibrinated SNBTS
Z8 factor VIII.
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6.2 Molecular weight cut off filters
In two series defibrinated factor VIII was filtered through Amicon Centriprep
ultrafiltration devices to give broad molecular weight fractions.
In the first series, when fractions were assayed in a weak one-way mixed lymphocyte
reaction, the enhancing activity was confined to fractions of >100 KDa molecular
weight (Fig 39). The results are expressed in terms of cumulative total 3H-thymidine
incorporation for the period of the assay, in counts perminute.
On further filter fractionation the activity was found to be in the fraction containing
components of molecular weight >30 KDa (Fig 40).
7 Fibronectin
Fibronectin is present at a considerable concentration in SNBTS Z8 and S8
concentrates. Human fibronectin did not enhance lymphocyte proliferation in response
to allogeneic lymphoblastoid cells when present at concentrations representative of those
in factor VIII preparations (Fig 41).
Peripheral blood mononuclear cells did not respond to fibronectin in the absence of
irradiated allogeneic stimulator cells. The fibronectin preparationwas not cytotoxic to
peripheral blood mononuclear cells.
8 Preincubation of SNBTS Z8 factor VIII with peripheral blood mononuclear cells or
irradiated lymphoblastoid cells
Significant enhancement of lymphocyte proliferation following stimulation with
irradiated allogeneic lymphoblastoid cells only occurred if factor VIII concentrate was
present throughout the culture period (Fig 42).
Peripheral blood mononuclear cells incubated with factor VIII overnight, then
stimulated with irradiated allogeneic lymphoblastoid cells responded weakly, with
limited 3H-thymidine incorporation. Transformation was limited when irradiated
lymphoblastoid cells were incubated with factor VIII overnight and then used to
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Molecular weight cut off filters were used to crudely fractionate defibrinated
SNBTS Z8 factor VIII. Fractions were assayed in the one way mixed lymphocyte
reaction and results expressed in terms of cumulative total 3H-thymidine
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Molecular weight cut off filters were used to crudely fractionate defibrinated
SNBTS Z8 factor VIII. Fractions were assayed in the one way mixed lymphocyte
reaction and results expressed in terms of cumulative total 3H-thymidine










































Molecular weight cut off filters were used to crudely fractionate defibrinated
SNBTS Z8 factor VIII. Fractions were assayed in the one way mixed
lymphocyte reaction and results expressed in terms of cumulative total
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Fig 41
Proliferation in the one way mixed lymphocyte reaction was not enhanced by the
presence of fibronectin. Purified human fibronectin was included at a range of
concentrations representative of those found in SNBTS blood products.
PREINCUBATION OF SNBTS FACTOR VIII (Z8-92450)





-o- PBMC:LCL Factor VIII through out
PBMC incubated with Factor VIII overnight:LCL
-a- PBMC1CL incubated with Factor VIII overnight
PBMC incubated with Factor VIII overnight:LCL incubated with Factor VIII overnight
DAYS INCUBATION
Fig 42
Effect of preincubation of PBMC or irradiated lymphoblastoid cells with factor
VIII concentrate prior to inclusion in a mixed lymphocyte reaction. Enhancement
of lymphocyte proliferation following stimulation with irradiated lymphoblastoid
cells was dependent on the continued presence of SNBTS Z8 concentrate.
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mononuclear cells and irradiated lymphoblastoid cells incubated with factor VIII
overnight, then washed extensively, reacted weakly when cultured together in a
one-way mixed lymphocyte response.
9 Incubation of SNBTS Z8 factor VIII with fresh, fixed, or irradiated
lymphoblastoid cells
Peripheral blood mononuclear cells did not respond well to paraformaldehyde fixed
allogeneic lymphoblastoid cells, except when factor VIII was present throughout the
culture period (Fig 43). The degree of lymphocyte transformation observed was similar
to proliferation in response to irradiated lymphoblastoid cells when SNBTS intermediate
purity concentrate was present throughout.
Lymphoblastoid cells incubated with factor VIII for four hours prior to fixation did not
stimulate peripheral blood mononuclear cells.
10 SDS-PAGE
10.1 Composition of factor VIII concentrates
A range of factor VIII products were electrophoresed in SDS-polyacrylamide gel slabs.
Samples were run in both reduced and non reduced forms.
Intermediate purity factor VIII concentrates ran very poorly due to the presence of high
molecular weight components (Fig 44, 45).
It is acknowledged that factor VIII concentrates comprise very complex mixtures of
plasma proteins at high concentrations. These include albumin, fibrinogen,
fibronectin and von Willebrand factor/factor VIII complexes which can have molecular
weights of 2 Mega Daltons or more. These mixtures are inherantly difficult to handle in
biochemical assays, partly because they tend to clot very easily.
Defibrination as described in Materials and Methods section 6.4, probably removed a
considerable range of other proteins besides fibrinogen. Following electrophoresis of
this material on a 1% polyacrylamide gel, it is evident that many of the components
INCUBATION OF SNBTS FACTOR VIII (Z8-92490) WITH
FRESH, FIXED, OR IRRADIATED
LYMPHOBLASTOID CELLS
-Q- PBMC :fixed LCL
PBMC:fixed LCL, subsequently incubated with Factor VIII for 4 hrs
PBMC:fixed LCL, incubated with Factor VIII throughout
-»-PBMC:LCL, incubated with Factor VIII for 4 hrs prior to fixation
* PBMC:irradiated LCL

















Enhanced lymphocyte proliferation in the one way mixed lymphocyte reaction was
dependent upon the continued presence of irradiated or fixed lymphoblastoid cells
and SNBTS Z8 factor VIII. Lymphoblastoid cells incubated with factor VIII for
four hours before or after fixation did not stimulate lymphocyte proliferation.
1 2 3 4 5 6 78 9101112131415
LANE NON
NUMBER SAMPLE REDUCED REDUCED
1 Marker +
2 SNBTS Z8-92340 +
3 SNBTS Z8-92340 defibrinated +
4 SNBTS S8-0006 +
5 Bio-transfusion +
6 Monoclate-P +
7 BPL 8Y FHC-01 10 +
8 Marker +
9 SNBTS Z8-92340 +
10 SNBTS Z8-92340 defibrinated +
1 1 SNBTS S8-0006 +
12 Bio-transfusion +
13 Monoclate-P +
14 BPL 8Y FHC-01 10 +
15 Marker +
Fig 44












SDS polyacrylamide gel of SNBTS prototype high purity factor VIII concentrate,
S8; SNBTS factor IX concentrate and purified human fibronectin.
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remain (Fig 44, lanes 2, 3, 9, 10). There has perhaps been some reduction in the
relative quantity of high molecular weight material remaining near the origin and a
corresponding increase in the proportion of albumin (the major heavy band of molecular
weight approximately 60 K).
The 'higher purity' preparations (SNBTS S8, Monoclate-P, Bio-transfusion and BPL)
have, as expected, fewer protein bands than intermediate purity SNBTS Z8. The
albumin added as stabilising material in Monoclate-P is very obvious (lanes 6 and 13,
Fig 44).
SNBTS factor IX also appears to comprise a complex mixture of proteins (Fig 45,
lanes 2). The faint band of approximately 55 K may be factor IX, which has a
molecular weight of 55.4 K. (Putman, 1975).
In general, however, the contaminant protein bands observed under both reducing and
non-reducing conditions cannot be identified with certainty.
10.2 Electrophoretic profile following filter fractionation
Defibrinated SNBTS factor VIII was fractionated using Amicon Centriprep ultrafiltration
devices. The fractions obtained were electrophoresed in a SDS-polyacrylamide gel slab
(Fig 46).
Similar protein bands are present in both defibrinated factor VIII and the > 100 K
fraction of factor VIII (Fig 46, lanes 2 and 3). The presence of protein of < 100 K in
the >100 K sample does not necessarily mean the fractionation process was
unsuccessful. Proteins comprising a number of subunits of < 100 K, but with total
molecular weight of >100 K would retained by the >100 K filter fraction, but appear
< 100 K molecular weight under the denaturing conditions of SDS-PAGE. Very little
protein is visible in the <100 K filter fraction (Fig 46, lanes 4). It is apparant that the
Centricon cut off filters could not cope with the large concentrations of protein present in
this material.
11 Selective protein depletion
Proteins were targeted for removal from SNBTS Z8-92490 factor VIII concentrate by
immunomagnetic isolation. The samples obtained were theoretically selectively










2 SNBTS Z8-92520 defibrinated
3 SNBTS Z8-92520 >100K filter fraction
4 SNBTS Z8-92520 < 100K filter fraction
Fig 46
SDS polyacrylamide gel of defibrinated filtered SNBTS Z8 factor VIII
concentrate.
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depleted of factor VHI/von Willebrands factor, fibronectin and HLA.DR proteins.
When included in lymphocyte proliferation assays all three 'depleted' samples enhanced
3H-thymidine incorporation in response to irradiated allogeneic lymphoblastoid cells.
Control buffer did not enhance proliferation is this assay (Fig 47).
It should be noted that selective protein depletion in this assay was highly improbable
due to the presence of inadequate amounts of antibody. For effective protein depletion
antibody should have been present in excess. Alternatively proteins could have been
removed from factor VIII concentrate following immunoaffinity chromatography using
specific antibodies coupled to protein A or protein G sepharose beads.
12 SNBTS factor VIII and HLA.DR expression in lymphoblastoid cells
Proliferation in response to allogeneic cells is strongly dependent on HLA. DR
recognition. The expression of HLA. DR antigens by the lymphoblastoid cell line
RABI2 was therefore investigated following incubation in the presence or absence of
intermediate purity SNBTS factor VIII concentrate.
Factor VIII concentrate did not alter the expression of HLA.DR antigens on irradiated
lymphoblastoid cells at the two time points studied (Fig 48).
13 SNBTS factor VIII and cell viability
The effect of Scottish factor VIII on the viability of peripheral blood mononuclear cells
and irradiated lymphoblastoid cells was measured by nigrosin dye exclusion.
Viability of peripheral blood mononuclear cells and in particular irradiated
lymphoblastoid cells was reduced over time. In the presence of factor VIII concentrate
cell viability declined less rapidly. The percentage of nigrosin positive cells was
significantly reduced in the presence of liu/ml SNBTS factor VIII at both 24 and 48










LCL PBMC MLR MLR MLR MLR MLR MLR
*1 *2 *3 #4 #5 *6
MLR *1 PBMC1CL
MLR *2 PBMC1CL Buffer 1/12
MLR *3 PBMC:LCL Factor VIII depleted of HLA.DR 1/12
MLR #4 PBMC1CL Factor VIII depleted of Fibronectin 1/12
MLR #5 PBMC1CL Factor VIII depleted of Factor VIll/von Willebrands Factor 1/12
MLR *6 PBMC:LCL Factor VIII 1/12 (1 iu/ml)
Fig 47
Several protein constituents of factor VIII concentrate were targeted for depletion
using immunomagnetic isolation. Depleted samples were assayed for
co-mitogenic activity in the mixed lymphocyte reaction.
The expression of HLA.DR on the human B cell line RABh following incubation
in the presence or absence of 2iu/ml SNBTS Z8 factor VIII concentrate.
A RABI2 incubated in culture medium, 24 hours
B RABI2 incubated in culture medium supplemented with SNBTS factor VIII, 24 hours
C RABI2 incubated in culture medium, 48 hours
D RABI2 incubated in culture medium supplemented with SNBTS factor VIII, 48 hours
Fig 48
SNBTS factor VIII concentrate did not alter the expression of HLA.DR
antigens on irradiated lymphoblastoid cells at two time points studied.







PBMC 1.5 10 19.5
LCL 15 48.5 62
PBMC incubated with FACTOR VIII 1.5 3.5f 2.2*
LCL incubated with FACTOR VIII 15 16f 21f
r P <0.01
Table 5
Viability of PBMC and LCL in the presence or absence of 1 iu/ml SNBTS
Z8 factor VIII.
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14 Mixed lymphocyte reactions and culture media
Lymphocyte proliferation in response to irradiated allogeneic lymphoblastoid cells was
fairly limited when cells were cultured in medium supplemented with 5%
heat-inactivated foetal calf serum. In contrast, cells grown in medium containing 10%
autologous plasma responded well to allogeneic stimulator cells.
SNBTS intermediate purity factor VIII did not further enhance lymphocyte proliferation
in a one-way mixed lymphocyte reaction performed in culture medium supplemented
with 10% autologous plasma (Fig 49). Similarly, control buffer did not affect
3H-thymidine incorporation in response to irradiated allogeneic cells when culture
medium contained autologous plasma (Fig 50).
15 Lymphocyte proliferation assays and HIV infection
15.1 PHA stimulation
Peripheral blood mononuclear cells were infected with HIV prior to stimulation with
PHA and incubated in the presence or absence of SNBTS intermediate purity factor VIII
concentrate.
Factor VIII inhibited 3H-thymidine incorporation in response to PHA in a
dose-dependent manner. Virus replication, as assessed by HIV p24 antigen
production, was reduced in the presence of factor VIII concentrate (Fig 51).
Lymphocyte proliferation curves for mock infected peripheral blood mononuclear cells
were similar to those for HIV-infected lymphocytes. Mock infected control cultures
were consistantly negative for HIV p24 antigen.
15.2 One-way mixed lymphocyte reactions
Peripheral blood mononuclear cells were infected with HIV prior to inclusion in a weak
one-way mixed lymphocyte reaction and incubated in the presence or absence of
SNBTS intermediate purity factor VIII.
3H-thymidine incorporation was significantly enhanced in the presence of SNBTS Z8






-o-PBMC:LCL Factor VIII liu/ml
♦ PBMCiCL Factor VIII 0.5iu/ml
•a- PBMC:LCL Factor VIII O.liu/ml
DAYS INCUBATION
Fig 49
SNBTS Z8 factor VIII did not effect lymphocyte proliferation in response to
irradiated allogeneic stimulator cells when cultured in growth medium






-o- PBMC1CL BUFFER 1/9 dilution
PBMC1CL BUFFER 1/18 dilution
-o- PBMC1CL BUFFER 1/90 dilution
DAYS INCUBATION
Fig 50
SNBTS control buffer did not effect lymphocyte proliferation in response to
irradiated allogeneic stimulator cells when cultured in growth medium
























PHA 5jjg/ml Factor VIII 1 iu/ml
PHA 5pg/ml Factor VIII 0.5iu/ml
-•-PHA 5Mg/ml Factor VIII 0.1iu/ml
DAYS INCUBATION
Fig 51
Inhibition of lymphocyte proliferation and HIV virus proliferation as measured by
3H-thymidine incorporation and p24 antigen production respectively in the
presence or absence of SNBTS Z8 factor VIII. Lymphocytes were stimulated
with 5 |xg/ml PHA. Total protein included per assay ranged from 0.26 mg/ml to
2.56 mg/ml.
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lymphocyte proliferation (Fig 52).
Peripheral blood mononuclear cells did not respond to factor VIII in the absence of
irradiated allogeneic stimulator cells. Similarly, p24 antigen was not detected in
cultures containing peripheral blood mononuclear cells and factor VIII alone.
Mock infected lymphocytes showed enhanced 3H-thymidine incorporation in a weak
one-way mixed lymphocyte reaction in the presence of factorVIII. Mock infected
control cultures were negative for p24 antigen throughout.
16 Mixed lymphocyte reactions in haemophilia patients
16.1 HIV antibody negative
Two HIV antibody negative haemophilia patients responded well to irradiated allogeneic
stimulator cells, when cultured in medium containing 10% autologous plasma. Factor
VIII did not enhance proliferation in the one-way mixed lymphocyte reaction over a
range of doses (Fig 53, 54).
Neither patient responded to factor VIII concentrate alone.
16.2 HIV antibody positive
Peripheral blood mononuclear cells from two HIV antibody positive haemophilia
patients were stimulated with irradiated allogeneic lymphoblastoid cells in a one-way
mixed lymphocyte reaction.
Cells from patient (3) were cultured in medium containing 5% pooled (AB) human
serum, while those from patient (4) were maintained in medium supplemented with
10% autologous heat-inactivated plasma.
Patient lymphocytes did not respond well in one-way mixed lymphocyte cultures.
Although some proliferation was evident on day two or three of culture, 3H-thymidine
incorporation decreased with time. On the whole 3H-thymidine incorporation was very
low.
SNBTS factor VIII appeared to enhance proliferation in response to stimulator cells to
some extent (Fig 55, 57). Control buffer or Monoclate-P factor VIII concentrate did










































-o-PBMC:LCL Factor VIII 2iu/ml
♦ PBMC1CL Factor VIII 1iu/ml









Enhanced lymphocyte proliferation and HIV replication as measured by
3H-thymidine incorporation and p24 antigen production respectively in the one
way mixed lymphocyte reaction. Lymphocytes were stimulated with irradiated
allogeneic stimulator cells. Total protein included per assay ranged from 1.28
mg/ml to 5.11 mg/ml.
SNBTS Z8-02970
AUTOLOGOUS PLASMA




-©- PBMC1CL Factor VIII 2iu/ml




SNBTS Z8 factor VIII did not effect lymphocyte proliferation in a mixed
lymphocyte reaction including lymphocytes from a HIV sero-negative
haemophilia patient. The proliferation assay was performed in growth
medium containing 10% autologous plasma.
SNBTS Z8-02870
AUTOLOGOUS PLASMA




-o- PBMC1CL Factor VIII 2iu/ml




SNBTS Z8 factor VIII did not effect lymphocyte proliferation in a mixed
lymphocyte reaction including lymphocytes from a HIV sero-negative
haemophilia patient. The proliferation assay was performed in growth
medium containing 10% autologous plasma.
SNBTS Z8-92520
HIV-antibody positive haemophilia patient (3)




-0- PBMC1CL Factor VIII 1 iu/ml




Effect of SNBTS Z8 factor VIII concentrate on lymphocyte
proliferation in the mixed lymphocyte reaction in a HIV
sero-positive haemophilia patient. The proliferation assay was
performed in growth medium containing 5% pooled (AB) human
serum. Total protein included per assay ranged from 0.22 mg/ml
to 2.18 mg/ml.
SNBTS BUFFER
HIV-antibody positive haemophilia patient (3)




-«-PBMC:LCL BUFFER 1/10 dilution




Effect of SNBTS control buffer on lymphocyte proliferation in
the mixed lymphocyte reaction in a HIV sero positive
haemophilia patient. The proliferation assay was performed in
growth medium containing 5% pooled (AB) human serum.
SNBTS Z8-92520
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Lymphocyte proliferation and HIV replication as measured by 3H-thymidine
incorporation and p24 antigen production respectively in the mixed
lymphocyte reaction in a HIV antibody positive haemophilia patient.
Cultures were performed in medium containing 10% autologous
heat-inactivated plasma in the presence or absence of SNBTS Z8 factor VIII.
Total protein included per assay ranged from 0.22 mg/ml to 2.18 mg/ml.
SNBTS BUFFER



































-«-PBMC:LCL Buffer 1/10 dilution













Lymphocyte proliferation and HIV replication as measured by 3H-thymidine
incorporation and p24 antigen production respectively in the mixed lymphocyte
reaction in a HIV antibody positive haemophilia patient. Cultures were performed
in medium containing 10% autologous heat-inactivated plasma in the presence or
































-o- PBMC1CL Factor VIII liu/ml












Lymphocyte proliferation and HIV replication as measured by
3H-thymidine incorporation and p24 antigen produaion respeaively in
the mixed lymphocyte reaction in a HIV antibody positive haemophilia
patient. Cultures were performed in medium containing 10%
autologous heat-inactivated plasma in the presence or absence of
monoclonal antibody purified Monoclate-P factor VIII concentrate.
Total protein included per assay ranged from 7.5 X 10-3 to 7.5 X 10-2.
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HIV p24 antigen was not detected in cell culture supernatants from patient (3). In
patient (4), p24 antigen was detected in cultures stimulated with irradiated
lymphoblastoid cells in the presence or absence of SNBTS Z8, control buffer and
Mononclate-P (Fig 57, 58, 59).
There did not appear to be any correlation between lymphocyte proliferation and HIV
p24 antigen production.
Neither patient responded to factor VIII alone, either by lymphocyte proliferation or by
p24 antigen production.
The effects of different factor concentrates on various lymphocyte proliferation assays
are summarised in Table 6.
TABLE 6
Summary of the effects of different factor VIII concentrates in various proliferation
assay systems.
KEY
+ + + ENHANCED
INHIBITED
+ /- NO EFFECT
++/— ENHANCED AND INHIBITED (concentration dependent)
- INHIBITED AT HIGH CONCENTRATION ONLY








































































































































In agreement with a number of published studies (Froebel et al, 1983, Lederman et al,
1986, Hay et al, 1990) I have demonstrated that intermediate purity factor VIII
concentrates can modulate immune reactions in vitro.
1 Effects of factorVIII concentrate on lymphocyte proliferation following stimulation
with phytohaemagglutinin
Lymphocyte proliferation in response to the non-specific T cell mitogen PHA was
severely depressed in the presence of high levels of SNBTS Z8 factor VIII concentrate.
McDonald et al (1985) reported that inhibition of lymphocyte transformation by Scottish
factor VIII could be reproduced when buffers used in the manufacture of factor VIII
were substituted for the concentrates themselves. The authors proposed that citrate
present in buffer and concentrate inhibited lymphocyte transformation by reducing the
availability of calcium ions required for lymphocyte activation in vitro. However, in
that study 3H-thymidine incorporation was assessed at one time point only, 50 hours
aftermitogen stimulation.
My own studies have also shown that 3H-thymidine incorporation in response to PHA
stimulation is reduced in the presence of SNBTS control buffer early after mitogen
stimulation. However, this appears to reflect a delay in lymphocyte transformation
rather than true inhibition of the proliferative response.
Citrate present in intermediate purity factor VIII concentrate may contribute to the
phenomenom in vitro by delaying lymphocyte transformation. Some other
component(s) of factor VIII concentrate inhibits lymphocyte proliferation in response to
PHA.
The inhibitory substance is unlikely to be factor VIII itself, as a range of high purity
concentrates have no effect on 3H-thymidine incorporation in response to PHA
stimulation. Two groups have shown that human factor VIII purified from
cryoprecipitate by large-pore gel filtration is not inhibitory to lymphocyte proliferation in
response to PHA stimulation (Wang et al, 1985, Dauletal, 1985). Similarly,
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monoclonal antibody purified Monoclate is totally devoid of immunosuppressive activity
in a PHA stimulation assay at a range of concentrations (Schreiber et al, 1987).
Albumin is unlikely to cause inhibition in vitro. Human albumin is included at high
concentrations in the preparations Monoclate, Hemofil-M and Monoclate-P as a
stabiliser. These concentrates do not inhibit lymphocyte proliferation in vitro.
SNBTS salt-poor albumin is reported to be strongly inhibitory to lymphocyte
transformation in \itro (McDonald et al, 1985). However, following the removal of
citrate and other salts by dialysis, this preparation becomes non-inhibitory, supporting
the interpretation that albumin plays no part in this phenomenom.
Freshly reconstituted SNBTS factor VIII that had been syringe filtered through a
membrane of 0.2|xm pore diameter was found to inhibit lymphocyte proliferation in
response to PHA. This type of syringe filter should remove protein aggregates. It is
therefore unlikely that large protein aggregates are the inhibitory component of SNBTS
factor VIII preparations.
Schultz and Shahidi (1990) have recently shown that fibronectin is a potent inhibitor of
lymphocyte reactivity in vitro, both in purified form and in plasma. The authors
demonstrate that purified human fibronectin depresses PHA induced mitogenesis in a
concentration-dependent manner over a dose range of 100-400 |ig/ml. Similar levels of
fibronectin certainly are present when intermediate purity factor VIII concentrates are
included in lymphocyte proliferation assays. It is likely that the fibronectin component
of factor VIII preparations contributes to inhibition of lymphocyte proliferation in
response to PHA in vitro.
The effect of purified human fibronectin on lymphocyte activation by PHA should
obviously be confirmed using various assay systems eg. 3H-thymidine incorporation,
IL2 production and cell surface activation marker expression. If fibronectin is the
immunosuppressive component of intermediate purity factor VIII concentrates, then
selective removal of fibronectin should also remove the inhibitory activity from
immunosuppressive concentrates. This could be achieved by immunoaffinity
chromatography using a monoclonal antibody specific for fibronectin. In the present
study immunomagnetic isolation was employed in order to deplete SNBTS Z8 factor
VIII concentrate of fibronectin. However, the extent to which fibronectin was
removed using this approach was not confirmed.
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Patients receiving factor IX concentrates appear to have fewer immune abnormalities in
\ivo when compared to haemophiliacs receiving factor VIII concentrates (Lee et al,
1984). In addition, factor IX concentrates have substantially lower fibronectin content
compared to intermediate purity factor VIII concentrates. However, SNBTS factor IX
concentrate inhibited lymphocyte transformation in vitro in response to PHA.
Inhibition may be due to some contaminant other than fibronectin present in factor IX
concentrate. It is interesting to note that the concentration of citrate in SNBTS factor IX
is approximately three times that in SNBTS factor VIII concentrate.
Inhibition of lymphocyte transformation by SNBTS factor IX concentrate may have
been complicated by lectin-glycoprotein interactions. This factor IX preparation has
been shown to bind to PHA immobilized on agarose, but not to othermitogen-agarose
gels (McDonald et al, 1985). SNBTS factor IX may therefore inhibit lymphocyte
proliferation indirectly by reducing the concentration of PHA available for the
stimulation of cells. In contrast, SNBTS factor VIII concentrate did not bind to
agarose-PHA gels.
Lymphocytes stimulated with PHA and incubated in the presence of intermediate purity
factor VIII concentrate express reduced levels of cell surface activation markers CD25
and CD71. This observation has been recently reported by Hay et al (1990), who
demonstrate that factorVIII concentrate causes not only reduced numbers of T
lymphocytes bearing activationmarkers, but reduced numbers of activation antigens per
cell.
The effect of SNBTS factor VIII on lymphocyte activation marker expression is dose
related. Factor VIII does not cause non-specific down regulation of all cell surface
molecules as the expression of CD44 remains constant over a range of factor VIII
concentrations.
The percentage of cells staining positive for CD25 and CD71 was reduced when
SNBTS control buffer was present at a high concentration. This may reflect delayed
lymphocyte activation rather than inhibition of cell proliferation. Activation marker
expression has been assessed at one time point only.
In accordance with the 3H-thymidine uptake results, monoclonal antibody-purified
factor VIII, Monoclate-P, had no effect on lymphocyte cell surface activation marker
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expression. Factor VIII itself and albumin are therefore unlikely to be responsible for
reduced cell surface activation marker expression.
The prototype higher purity SNBTS factor VIII concentrate S8 behaved in a similar
manner to conventional intermediate purity Z8 concentrate in this assay in vitro.
SNBTS S8 factor VIII concentrate has significantly lower fibrinogen content compared
to SNBTS Z8. It is therefore unlikely that fibrinogen is the protein contaminant
responsible for reduced cell surface activation marker expression following PHA
stimulation. Although both concentrates have similar citrate contents, SNBTS S8 has
an approximately two fold higher fibronectin content compared with SNBTS Z8.
Unfortunately, time did not permit the inclusion of SNBTS S8 in a conventional
3H-thymidine uptake assay.
The percentage of cells staining positive for HLA.DR was rather low throughout. It is
possible that the time point chosen for cell surface marker analysis was not optimal for
HLA. DR expression. Cell surface activation marker expression may well be influenced
by the concentration of stimulatory mitogen used, type of culture medium or the
concentration of cells cultured. Alternatively, the monoclonal antibody used in the
assay may not have had high affinity for HLA. DR. This seems unlikely as initial
titration of the monoclonal antibody against a cell line expressing HLA. DR was
satisfactory (Data not shown).
Lymphocytes stimulated with PHA and incubated in the presence of intermediate purity
factorVIII concentrates produced lower levels of IL2 compared to control cultures. IL2
levels were reduced at both 24 and 48 hours post stimulation. Factor VIII was not
directly responsible for reduced 3H-thymidine incorporation by the IL2 dependent cell
line as proliferation in response to recombinant IL2 was not affected by the presence of
factor VIII. The effect of control buffer on IL2 secretion following PHA stimulation
was not investigated.
The inhibitory effect of factor VIII concentrate on IL2 secretion by human T cells has
been demonstrated by Lederman et al (1986) and Thorpe et al (1989). The
component(s) of factor VIII preparations responsible for reduced IL2 secretion in vitro
has not yet been identified.
Factor VIII concentrate inhibited lymphocyte proliferation only when present throughout
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the culture period. Peripheral blood mononuclear cells incubated with factor VIII
overnight and then washed extensively responded normally to PHA. My results
contrast with those of Lederman et al (1986) who report that prolonged incubation of
lymphocytes with lyophilized factor VIII concentrate resulted in an irreversible inhibition
of proliferative responses to PHA. The two studies are not directly comparable as
different factor VIII concentrates were investigated under different in vitro culture
conditions. In particular, the concentration of PHA mitogen used to stimulate
lymphocytes was not the same.
The levels of factor VIII required to cause significant inhibition of lymphocyte
proliferation in vitro in response to PHA were generally high. Lymphocyte
proliferation assays in the continued presence of high levels of factor VIII concentrate in
vitro are therefore somewhat artificial. During factor VIII substitution therapy, levels
of factor VIII are high for a brief period before dropping to baseline. The half-life of
factor VIII activity for most concentrates is approximately 13 hours (Berntorp and
Nilsson, 1988). The half-life values for various contaminant components of factor
VIII concentrate are however unknown. The relevance of this type of assay to the
situation in \ivo is therefore questionable.
In summary, intermediate purity factor VIII concentrate appears to inhibit lymphocyte
function by interfering with an early activation event which, in turn, leads to reduced
cell surface activation marker expression and inhibition of IL2 secretion. The
component responsible for this in vitro effect has not been identified but fibronectin is a
candidate. Citrate contributes to altered lymphocyte function by delaying
transformation. High purity factor VIII preparations have no effect on PHA stimulation
in vitro.
2 SNBTS batch Z8-6026
SNBTS batch Z8-6026 inhibited lymphocyte proliferation in response to PHA when
present at high concentrations, but enhanced proliferation over a lower dose range.
Similar effects were observed when lymphocytes were stimulated with the recall antigen
tetanus toxoid or a suboptimal dose of pokeweed mitogen. SNBTS batch Z8-6026 on
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its own did not stimulate lymphocyte proliferation, but seemed to act as a co-mitogen,
boosting weak proliferative responses.
This batch of factor VIII was manufactured early in 1987 and was heat treated at 80°C
for 72 hours, as is normal. When compared to other batches of Z8 assayed (Appendix
I), Z8-6026 has significantly lower fibronectin content. The reduced inhibitory activity
of this batch of factor VIII may therefore be related to low fibronectin. Citrate present
in the factor VIII formulationmay be responsible for delaying lymphocyte proliferation
when included at a high concentration.
It is possible that in the absence of inhibitory fibronectin, humoral growth factors,
nutrients and cofactors enhance proliferation in response to PHA.
SNBTS Z8-6026 was one of two batches of factor VIII manufactured from ' FB1 type
plasma. The majority of batches of factor VIII are manufactured from plasma collected
and frozen within eight hours ('FA' type plasma). Plasma for SNBTS batches
Z8-6026 and Z8-92340 was collected and frozen within eighteen hours. Theoretically,
such factor VIII concentrate could contain a higher concentration of degraded proteins or
cell surface molecules such as HLA antigens and blood group antigens. However,
SNBTS batch Z8-92340 did not enhance lymphocyte proliferation in response to PHA
stimulation over a range of concentrations tested. The effect is therefore unlikely to be
related to duration of plasma storage.
Lederman et al (1986) fractionated factor VIII concentrate by gel filtration and analysed
fractions for inhibitory activity in PHA stimulation assays. It is interesting to note that
along with two inhibitory fractions, intermediate fractions from some preparations
actually enhanced lymphocyte proliferative responses to PHA. These fractions had no
effect on unstimulated lymphocyte cultures.
3 Effects of factor VIII concentrate on lymphocyte proliferation following stimulation
with irradiated allogeneic lymphoblastoid cells
A range of factor VIII preparations was assayed in a weak one-way mixed lymphocyte
reaction in vitro. Lymphocyte proliferation in the presence of allogeneic stimulator
cells was correlated with product purity.
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All batches of intermediate purity SNBTS Z8 factor VIII assayed enhanced lymphocyte
proliferation in this system. Responding cells comprised CD4+ and CD8+T cells
expressing a range of cell surface activation markers. Prototype higher purity SNBTS
S8 and BPL 8Y factor VIII concentrates enhanced the response to a lesser extent. In
contrast, all ultra-pure or monoclonal antibody purified products had no effect on
proliferation in this assay. Enhanced proliferation was not therefore due to factor VIII
itself nor to albumin. Similarly, SNBTS control buffer had no effect on proliferation
in response to allogeneic stimulator cells.
Protein aggregates are unlikely to be responsible for enhanced lymphocyte proliferation
as the removal of such aggregates by syringe filtering did not effect the co-mitogenic
properties of SNBTS factor VIII concentrate.
SNBTS factor IX concentrate enhanced the proliferative response in mixed lymphocyte
culture when present at a high concentration. It is unclearwhether the co-mitogenic
factor(s) present in SNBTS factor IX concentrate is the same as that in SNBTS Z8 and
S8 concentrates. The three concentrates do not have equivalent contaminating proteins;
for example, SNBTS factor IX concentrate contains very little fibrinogen or fibronectin,
proteins which are the main contaminants of SNBTS Z8 and S8 concentrates. The
concentrates may however contain a common, minor contaminant, responsible for this
phenomenom in \itra
None of the concentrates assayed was mitogenic alone. Some co-mitogenic factor(s) in
the preparations boosted a weak proliferative response.
Fractionating SNBTS factor VIII by conventional biochemical means proved to be
problematic. The concentrate tended to clot during preparative procedures such as
dialysis and during column fractionation. Several basic physical approaches were
therefore taken in attempt to characterise the factor(s) responsible for the effects
observed in \itro.
Freeze-thawing and filtering did not abrogate the co-mitogenic effect. The proliferative
response to irradiated allogeneic cells in the presence of defibrinated factor VIII was
only slightly reduced. It is unlikely that fibrinogen was completely removed from the
factor VIII concentrate. Analysis of 'defibrinated' Z8 factor VIII by SDS-PAGE
showed that the protein profile was similar to that of freshly reconstituted factor VIII,
but with fewer high molecular weight bands. The addition of thrombin to reconstituted
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factor VIII concentrate not only accelerates the formation of fibrin from fibrinogen
monomers, but activates factor VIII.
The contaminant responsible for enhanced proliferation in response to allogeneic
stimulator cells is unlikely to be fibrinogen. SNBTS factor IX and SNBTS S8
prototype factor VIII concentrates contain only low levels of fibrinogen but enhanced
proliferation in weak one-waymixed lymphocyte cultures.
SNBTS Z8 factor VIII concentrate was filtered through Amicon ultra filtration devices in
order to fractionate the constituents into broad molecular weight bands. The enhancing
activity appeared to be confined to the fraction containing molecules of 100 KDa or
over. However, SDS-PAGE analysis revealed the factor VIII had not been
fractionated efficiently. The protein profile of the '>100 KDa fraction' was identical to
that of the unfractioned defibrinated factor VIII. The '>100 KDa fraction' contained
molecules of < 100 KDa. Similarly, traces of high molecular weight molecules are
apparant in the '<100 KDa fraction'. In addition, the protein concentration in the
'<100KDa' fraction is very much lower than for defibrinated factor VIII or the '>100
KDa fraction'. The lack of enhanced cell proliferation by the '< 100 KDa fraction' may
therefore be due to dilution, rather than to absence of the factor responsible.
Defibrinated factor VIII was filtered through Amicon ultrafiltration devices with
molecular weight cut off values of 30 KDa and 10 KDa. When assayed in vitro the
enhancing activity was confined to the >30 KDa fraction. As SDS-PAGE analysis of
the fractions obtained was not performed, it is unclear if the fractions assayed in vitro
contained molecules only within the molecular weight range stated.
Klingemann et al (1986) demonstrated that fibronectin restored defective lymphocyte
proliferation in vitro in the mixed lymphocyte reaction of immunocompromised bone
marrow transplant patients. Fibronectin and monoclonal antibodies specific for CD3
have also been shown to be costimulants of human CD4 positive lymphocyte
proliferation under appropriate culture conditions (Matsuyama et al, 1989, Shimizu et
al, 1990). It therefore seemed plausible that fibronectin, present in factor VIII
concentrates, may play a role in enhancing the mixed lymphocyte reaction in vitro.
However, a range of concentrations of purified fibronectin were assayed in vitro and
found to be completely devoid of co-mitogenic activity.
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Three protein contaminants present in SNBTS factor VIII were targeted for removal by
immunomagnetic isolation. Monoclonal antibodies to HLA.DR, fibronectin and factor
VHI/von Willebrand factor were immobilized on magnetic particles and incubated with
factor VIII concentrate. The resulting 'depleted' samples were included in a weak
one-way mixed lymphocyte reaction. All enhanced lymphocyte proliferation to the
same extent as untreated factor VIII concentrate. These three proteins may not therefore
be responsible for the observed effect. However, these results are preliminary; the
efficiency of protein depletion using this approach has not been confirmed.
It is not clear why some component of factor VIII enhances lymphocyte proliferation in
the presence of a weak allogeneic stimulus.
Matheson et al (1986) observed a positive blastogenic response to low concentrations of
lyophilized factor VIII concentrate in a seven day thymidine uptake assay. However,
responses were fairly weak and only occurred in haemophilia patients who had
previously been exposed to factor VIII concentrate. Peripheral blood mononuclear cells
from healthy controls did not respond to the factor VIII concentrate in vitro. The
presence of T cells primed to factor VIII in haemophilia patients has also been suggested
by Madhok et al (1991).
In contrast, I have observed that Scottish factor VIII enhanced the proliferative response
of non-haemophiliac cells to irradiated allogeneic lymphoblastoid cells. Responder
lymphocytes had not previously been exposed to factor VIII concentrate and could not
therefore be considered antigenically primed to some constituent of SNBTS Z8
concentrate.
B cells can process antigen efficiently and present the internalized derivative (Pierce et
al, 1988). It is therefore possible that the irradiated allogeneic lymphoblastoid B cells
are presenting some antigen(s) in the factor VIII concentrate. This seems unlikely in
view of the fact that allogeneic cells incubated with factor VIII overnight, then
extensively washed, do not enhance the mixed lymphocyte reaction in \itro.
Similarly, allogeneic cells incubated with factor VIII for four hours prior to fixation
with paraformaldehyde do not stimulate well in vitro. In contrast, fixed or irradiated
lymphoblastoid cells incubated with factor VIII concentrate throughout the culture period
are strongly stimulatory to peripheral blood mononuclear cells.
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Alloreactivity in vitro is controlled by polymorphic class II molecules encoded in the
major histocompatibility complex (Eckels D D, 1989). Cellular immune responses in
the mixed lymphocyte reaction are very much dependent on stimulator cell HLA. DR
expression. The expression of HLA.DR antigen by the lymphoblastoid stimulator cell
line was therefore investigated in the presence or absence of intermediate purity factor
VIII concentrate. However, SNBTS factor VIII concentrate did not alter the level of
expression of HLA. DR antigen. Increased HLA. DR expression did not contribute to
enhanced cell proliferation in vitro in the presence of factor VIII.
It is probable that the observed in vitro effect of factor VIII concentrate in this assay is
related to the availability of nutrients and growth factors. Peripheral blood mononuclear
cells and irradiated lymphblastoid cells remained viable for a longer period of time when
incubated in medium supplemented with factor VIII concentrate in addition to heat
inactivated foetal calf serum and fresh glutamine.
When mixed lymphocyte reactions were performed in medium supplemented with
autologous plasma, peripheral blood mononuclear cells responded well to irradiated
lymphoblastoid cells and neither SNBTS factor VIII nor control buffer affected the
response in any way. The co-mitogenic effect of factor VIII concentrate on
proliferation in response to allogeneic cells is only apparent under suboptimal culture
conditions. It seems likely that some substance present both in intermediate purity
factor VIII concentrate and in normal plasma is responsible for the effect observed in
vitro.
My results contrast those of Lederman et al (1986) who reported reduced lymphocyte
proliferation in response to allogeneic stimulator cells in the presence of lyophilized
factor VIII concentrate. It is difficult to compare these conflicting results as no technical
details of culture conditions used by the previous authors are available. In addition,
Lederman et al did not include NHS concentrate manufactured in the United Kingdom
but assayed three commercial American products.
4 Lymphocyte proliferation, factor VIII and HIV infection
Peripheral blood mononuclear cells from a healthy individual were infected with a
laboratory strain of HIV and included in proliferation assays in vitro.
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Lymphocyte proliferation in response to PHA was inhibited by SNBTS Z8 factor VIII
concentrate in a dose-dependent fashion. HIV replication, as assessed by p24 antigen
production approximated to lymphocyte proliferation. Similarly, p24 antigen
production correlated with lymphocyte proliferation in response to allogeneic stimulator
cells and intermediate purity factor VIII concentrate. It is not surprising that HIV
replication was related to lymphocyte proliferation as HIV is known to preferentially
infect, and replicate in activated T4 lymphocytes (Margolick and Fauci, 1987).
It must be stressed that no virus replication occurred in the presence of SNBTS factor
VIII alone. As in non HIV-infected lymphocytes, proliferation in response to
allogeneic stimulator cells was boosted in the presence of factor VIII.
I have demonstrated that intermediate purity factor VIII concentrate may modulate
immune reactivity and therefore HIV virus replication in vitro. Intermediate purity
factor VIII concentrate could potentially affect immune reactivity in vivo. PHA is not a
physiological stimulus but a non-specific T cell mitogen. The relevance of such
stimulation in xitro to the situation in xivo is therefore doubtful. In contrast,
lymphocyte proliferation in the mixed lymphocyte reaction in vitro is based on the
phenomenom of allograft rejection in vivo and may therefore be a more relevant
experimental model. If this is so, then the possibility arises that infusions of factor
VIII may enhance lymphocyte activation in response to naturally occurring immune
stimuli encountered in xivo. In an HIV antibody positive haemophilia patient this
could lead to increased virus replication and thus accelerated HIV disease progression.
To date, there has been no conclusive evidence to support a role for intermediate purity
factor VIII in accelerating HIV disease progression.
The effect of intermediate versus high purity factor VIII concentrate on HIV disease
progression is unresolved. Some groups claim high purity factor VIII preparations
stabilise immune parameters in HIV antibody positive haemophilia patients (Fukutake et
al, 1991, deBiasietal, 1991, Goldsmith et al, 1991). Others however, do not
support a beneficial role for high purity concentrates in the treatment of HIV antibody
positive haemophilia patients (Mannucci et al, 1991, Transfusion Safety Study [TSS]
Group, 1991).
Most studies have been in progress for short periods of time and may be more
informative in the future.
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In studies of this type it is essential that patient groups are correctly balanced. In
particular, patients should be matched in terms of HIV disease stage, blood product
usage and age, before being assigned to receive treatment with intermediate or high
purity factor VIII concentrate. The presence and severity or absence of liver disease
should also be considered in such prospective trials.
The response to treatment with high purity factor VIII concentrates may vary depending
on how far HIV disease has progressed. Patients may fare better on high purity factor
VIII products if they receive them early in the course of HIV disease, while their
immune system is relatively intact.
Unfortunately, it is impossible to investigate the effect of intermediate purity SNBTS
factor VIII concentrate on HIV disease progression in the Edinburgh haemophilia
cohort, as the group comprises only eighteen patients. A strong effect from the HLA
haplotype A1 B8 DR3 on HIV disease progression in this group of patients further
confounds such analysis.
5 Lymphocyte proliferation in haemophilia patients
The effect of SNBTS Z8 factor VIII concentrate on the proliferation of peripheral blood
mononuclear cells from haemophilia patients was investigated. However, as numbers
were extremely limited, the conclusions drawn are preliminary and should be
confirmed.
Immune reactivity to allogeneic stimulator cells was not impaired in HIV antibody
negative haemophilia patients. 3H-thymidine incorporation in response to irradiated
lymphoblastoid cells in medium supplemented with autologous plasma was comparable
to that found for non-haemophiliac bloods and was not enhanced by the presence of
SNBTS Z8 factor VIII concentrate. Haemophilia patients are not therefore
immunosuppressed with respect to alloantigens.
Mixed lymphocyte reactions using lymphocytes from haemophilia patients were not
conducted in medium containing heat inactivated foetal calf serum. It would obviously
be interesting to determine whether SNBTS factor VIII enhances lymphocyte
proliferation under these assay conditions.
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The behaviour of lymphocytes from haemophilia patients infected with HIV in one-way
mixed lymphocyte reactions in vitro was abnormal. Responses to irradiated allogeneic
stimulator cells were extremely poor and onlymarginally improved in the presence of
SNBTS factor VIII. The mixed lymphocyte reaction appeared to peak lower, early and
for a limited period of time. The response to allogeneic stimulator cells was not
sustained in HIV positive haemophilia patients.
In general, the response to allogeneic stimulator cells in vitro peaks around day five or
six of culture. In the HIV positive patients however, 3H-thymidine incorporation in
the one-way mixed lymphocyte reaction typically declined from day three.
3H-thymidine incorporation was not due to lymphocytes pre-activated in vivonot to
lymphoblastoid cells as both these cell types did not proliferate when cultured alone.
In the presence of SNBTS Z8 factor VIII concentrate lymphocytes may remain viable
and responsive to allogeneic stimulation for a short period, thus causing a small
increase in 3H-thymidine incorporation. SNBTS control buffer and monoclonal
antibody purified factor VIII did not affect 3H-thymidine incorporation in this assay.
Both haemophilia patients studied had been infected with HIV for over seven years and
displayed all the immunological characteristics of HIV disease progression. Patients
had low CD4+ T lymphocyte counts, high numbers of activated T cells and high levels
of circulating soluble IL2-receptor and serum P2microglobulin.
Virus proliferation in \itro was measured in terms of p24 antigen production. p24
antigen levels in one patient remained below the lower threshhold of the assay. In
contrast, p24 was readily detectable in cell supernatants from patient (4). The p24
levels did not correlate well with 3H-thymidine incorporation. Although the
concentration of p24 appears to be low, it should be noted that the virus assayed
originates from only 5X10* peripheral blood mononuclear cells. p24 antigen
production was presumably due to activation of cellular HIV provirus and not a result of
cell reinfection from autologous plasma. All plasma used to supplement culture
medium was heat inactivated prior to inclusion in the assay.
p24 antigen levels appear to increase in the presence of SNBTS Z8 factor VIII
concentrate, SNBTS control buffer and monoclonal antibody purified factor VIII. This
type of experiment should obviously be repeated in order to ascertain whether this rise is
reproducible or an artifact.
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Neither HIV antibody negative nor HIV antibody positive haemophilia patients appeared
to be antigenically primed to any component of SNBTS factor VIII concentrate as
peripheral blood mononuclear cells incubated with factor VIII concentrate did not
proliferate. In vitro immune reactivity to factorVIII concentrate has only rarely been
reported in haemophilia patients (Matheson et al, 1986, Madhoketal, 1991).
In conclusion, I have confirmed the immunomodulatory nature of factor VIII
preparations in vitro Immunomodulatory effects were observed using therapeutic
concentrations of factor VIII. The effects were related to the degree of purity of the
factor VIII preparation assayed. Factor VIII itself was not responsible for
immunomodulation in proliferation assays in vitro and the effects were probably not
due to fibronectin.
Effects on lymphocyte proliferation were still demonstrable in defibrinated SNBTS Z8
intermediate purity factor VIII concentrate, which was more amenable to
physico-chemical manipulation than the reconstituted preparation used for injection.
Initial attempts to define the molecular weight of the relevant contaminant responsible for
immune modulation in vitro where not successful.
Biological effects on lymphocyte proliferation in vitro were not observed in the
presence of 10% pooled (AB) human serum or heat treated autologous plasma. The
co-mitogenic contaminant present in factor VIII preparations may be a component of
normal human serum not found in foetal calf serum.
In order to clarify the relationship between the contaminant(s) responsible for immune
modulation in vitro and immunological abnormalities observed in haemophilia patients
treated with intermediate purity factor VIII products in vivo, the co-mitogenic activity
must first be further chemically characterised. This could involve for instance,
ultracentrifugation, to crudely seperate components of the concentrate. Specific
degrative enzymes such as proteases could also be used to characterise the component.
Alternatively, affinity columns could selectively remove specific components of
immunomodulatory preparations such as stimulatory cytokines, if present. More
subtle fractionation procedures such as high pressure liquid chromatography (HPLC)
will probably have to await removal of major non-contributing components (eg. by
ultracentrifugation).
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When identifed the candidate component should be selectively removed from
commercial factor VIII preparations. This could be achieved by immunoaffinity
chromatography. The depleted concentrates should notmodulate immune activity in
vitro. Factor VIII concentrates lacking the identified immunomodulatory component
should then be tested in vivo. Patient immune status (eg. reactivity to skin test
antigens) should be compared before and after receiving factor VIII concentrate without
the specific component. If the identified component is indeed responsible for immune
modulation, then immune function in patients receiving this material should show
improved immunological status in vivo. In addition, patients treated entirely with such
a depleted preparation should not develop any of the immunological abnormalities
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APPENDIX I
Appendix I lists batches of SNBTS Z8 factor VIII included in this study. All product





























































































1STAGEASSAY iu/ml 10.04 9.76 10.31 7.61 1.04 9.69 9.94 10.72 1.09 9.96 9.96 1.31 10.72 12.25 9.69 9.25 1.91 9.92 1.59
FACTORVIIl:
2STAGEASSAY iu/ml 6.26 6.06 6.39 3.57 7.50 7.08 7.97 7.20 6.69 6.18 6.23 7.89 8.43 7.93 7.98 8.22 9.32 7.77 10.03
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APPENDIX II
Appendix II summarises total protein concentration, factor VIII activity and mode of
virus inactivation for concentrates included in this study. Product information
presented is as stated in manufacturers' product insert or was provided by the SNBTS
Protein Fractionation Centre, Edinburgh.
APPENDIXII
FACTORVIII SNBTS BPL8Y PROFILATEHEAT-TREA ED OCTA-PHARMAV.1.250 BIO-TRANSFUSION HEMOFIL-M MONOCLATE MONOCLATE-P




10.36+/-1.07DRYHEAT802C72hours 23.5+/-3.1DRYHEAT80^c72hours 22WETHEATR ATED60Chours 25SOLVENT-DETERGENT 42.5+/-9.5SOLVENT-DETERGENT 31.1SOLVENT-DETERGENT 100DRYHEAT623hours 100PASTEURIZED6schours
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APPENDIX III
Appendix III compares SNBTS Z8, SNBTS S8 and SNBTS factor IX concentrates.
Product characteristics were kindly provided by the SNBTS Protein Fractionation
Centre, Edinburgh.
APPENDIX III






total protein g/i 23.3+/-1.6 15.5 16.2
fibrinogen g/i 9.60+/-1.68 4.2 0
fibronectin g/i 5.05+/-1.35 10.8 -
sodium mmol/l 151+/-4 193 232.0
chloride mmol/1 102+/-5 1 16 1.00
citrate mmol/l 21.9 + /- 1 27.5 59.2
PH 6.92+/-0.07 7.14 7.1 1
sucrose % 2.13+/-0.13 6.04 -
moisture % 1.14+/-0.31 0.7 -
zinc ppm 7.19+/-2.01 7.75 -
calcium ppm 122.5+/-12 1 15.0 -
osmolality mOsm/kg 326+/-11 522 -
aluminium ppb 70.2+/-23.2 258 -
VI11 :C 1 iu/ml 10.36+/- 1.07 20.24 -
VIII:C 2 iu/ml 7.15+/- 1.28 18.42 -
potassi urn mmol/l - 0.1 1 0.08
phosphate mmol/l - - 36.9
F IX iu/ml - - 37.07
Xa generation min - - 25
NAPTT sec - - 304
F II iu/ml - - 58.38
F X iu/ml - - 35.71
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